Introduction

Front. Nutr.

Frontiers in Nutrition

Front. Nutr.

2296-861X

Frontiers Media S.A.

10.3389/fnut.2025.1730053

Review

Plant-derived food bioactives in bone health: from multi-targeted roles to molecular mechanisms in osteoporosis

Zhang

¹ Writing – original draft Writing – review & editing Xu

Lijuan

¹ Investigation Writing – original draft Xu

Haofeng

¹ Investigation Project administration Writing – review & editing Zhang

Yiran

¹ Resources Visualization Writing – review & editing Wang

Linxiao

¹ Investigation Resources Writing – review & editing Jiang

Shasha

¹ Investigation Visualization Writing – review & editing Sun

Yan

² ^* Writing – review & editing Yu

Yan

¹ ^* Writing – review & editing

1Department of Clinical Laboratory, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China 2Honghui Hospital, Xi'an Jiaotong University, Xi'an, China

*Correspondence: Yan Sun, 1748842950@qq.com; Yan Yu, 732867304@qq.com

12 01 2026

2025

1730053

22 10 2025 06 12 2025 12 12 2025

2026

Zhang, Xu, Xu, Zhang, Wang, Jiang, Sun and Yu

https://creativecommons.org/licenses/by/4.0/

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Osteoporosis (OP) is a metabolic bone disease characterized by reduced bone mass and deterioration of bone microstructure. Current pharmacological treatments are often associated with significant side effects and poor patient compliance. In recent years, food bioactives—such as polyphenols, carotenoids, and saponins—have attracted growing interest for their multi-target and low-toxicity profiles in the prevention and management of OP. This review systematically elaborates the protective roles and underlying molecular mechanisms of these compounds against OP. Polyphenols exert beneficial effects through antioxidant, anti-inflammatory, and bone metabolism-regulating properties, as well as via modulation of the gut–bone axis. Their mechanisms involve key signaling pathways, including PI3K/Akt, sirtuin 1 (SIRT1)/forkhead box O3a (FOXO3a), Hippo/YAP, reactive oxygen species (ROS)/HIF-1α, and Wnt/β-catenin. Carotenoids, which are potent antioxidants, contribute to a reduced risk of OP by alleviating oxidative stress and cellular senescence, including the senescence-associated secretory phenotype (SASP). Saponins regulate bone remodeling bidirectionally through pathways such as PI3K/Akt/mTOR, bone morphogenetic protein 2 (BMP-2)/runt-related transcription factor 2 (Runx2), and RANKL/osteoprotegerin (OPG). They also inhibit NF-κB/mitogen-activated protein kinase (MAPK) signaling and downregulate osteoclast-related transcription factors, including c-Fos and NFATc1. Given their efficacy and safety, food bioactives represent a valuable source of novel nutraceuticals for bone health.

bone formation bone resorption carotenoids food bioactives osteoporosis polyphenols saponins

The author(s) declared that financial support was not received for this work and/or its publication.

section-at-acceptance

Nutrition and Food Science Technology

1 Introduction

Osteoporosis (OP) is a systemic skeletal disease characterized by micro-architectural deterioration of bone tissue and reduced bone mineral density (BMD), resulting in increased skeletal fragility and fracture susceptibility (1). Osteoporosis represents the most common bone disorder. Global data indicate that the incidence of osteoporotic fracture remains high, with a worldwide prevalence of 19.7% (10.6% in men and 24.8% in women) (2). The burden is most pronounced in regions undergoing rapid demographic aging. A 2024 survey, for example, reported an overall prevalence in China of 18.2% (11.5% male, 23.4% female), rising steadily with age—a stark illustration of the scale of the problem in the world's most populous nation (3). Similarly, 2023 figures from developed Asia-Pacific economies confirm that OP is already common across the region (4). With the global population continuing to age, this epidemiological trend is set to persist. The condition predominates in the elderly and in post-menopausal women, in whom the precipitous decline in estrogen leads to hormonal imbalance and accelerated bone loss (5, 6). Often referred to as a “silent disease,” OP is typically asymptomatic until a fragility fracture occurs—even after minor trauma or a fall from standing height. Such fractures are associated with considerable morbidity and increased mortality (7). Although genetic factors modulate mid-life BMD, age and modifiable lifestyle determinants now exert the dominant influence (8).

OP requires therapeutic intervention to upregulate BMD through pharmacological agents and/or natural compounds. Conventional treatments for bone diseases, however, are often associated with adverse effects. For instance, a meta-analysis found that patients receiving denosumab at osteoporotic doses experienced a higher incidence of serious infective adverse events (9). Current anti-osteoporotic medications consist of antiresorptive agents—such as bisphosphonates, cathepsin K (CTSK) inhibitors, and selective estrogen receptor modulators (10)—as well as vitamin D₃, the parathyroid hormone analog teriparatide, and the receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) monoclonal antibody denosumab (11). These treatments are linked to complications including hypercalcaemia, hypercalciuria, vasomotor symptoms, breast tenderness, thromboembolic events, and an elevated risk of endometrial or breast carcinoma (12). In contrast, plant-derived compounds have demonstrated the potential to improve skeletal health without the adverse effects commonly associated with synthetic pharmaceuticals (13, 14).

In recent years, plant-derived bioactives have emerged as rational candidates for promoting skeletal health (15). For centuries, functional molecules from edible-medicinal plants have been used to improve bone quality, and their use as dietary supplements for the prevention of osteoporosis is now considered feasible (16). Parallel advances in genomics, proteomics, transcriptomics and metabolomics have created an experimentally grounded route by which these botanical molecules can be translated into mainstream drug development. A substantial proportion exhibit measurable antioxidant, anti-inflammatory, antimicrobial and anti-carcinogenic activities (17–19). Mechanistically, they suppress bone loss, preserve micro-architecture and reduce fragility by attenuating oxidative stress, modulating autophagy, dampening inflammation, reshaping the gut microbiota and adjusting estrogen levels, all with a comparatively mild side-effect profile (16). Specifically, they can tilt the RANKL/osteoprotegerin (OPG) axis in favor of osteoblast survival—down-regulating RANKL while up-regulating OPG—thereby delivering anti-osteoporotic efficacy (20, 21). Nevertheless, concentration- and structure-dependent issues of toxicity, drug–drug interaction and physicochemical stability mandate full pre-clinical and clinical evaluation before any botanical bioactive can be recommended routinely (17, 18). Despite these challenges, such natural compounds remain a highly attractive alternative to synthetic drugs whose adverse-event burden is often appreciably higher (17). Among the array of plant-derived compounds, the polyphenols, carotenoids and saponins have emerged as the most persuasive agents. They beneficially re-programme bone metabolism by curbing resorption, conserving bone-mineral density and blocking osteoclast differentiation (22–24). Consequently, we systematically reviewed the roles and mechanisms of the currently most promising plant-derived bioactive substances—polyphenols, carotenoids, and saponins—in osteoporosis, providing a potential, multi-targeted, and low-toxicity alternative to conventional therapeutic approaches for the management of osteoporosis.

2 Literature search strategy

A systematic literature search was conducted to identify all relevant studies on plant-derived food bioactives (polyphenols, carotenoids, and saponins) and their role in osteoporosis (OP). The primary database searched was PubMed/MEDLINE. The search strategy was built using Medical Subject Headings (MeSH) terms and key free-text words to ensure a comprehensive retrieval of records. The core search concepts included:

Bioactive Compounds: “Polyphenols” [Mesh] OR “Carotenoids” [Mesh] OR “Saponins” [Mesh] OR “Phytochemicals” [Mesh]

Disease/Condition: “Osteoporosis” [Mesh] OR “Osteogenesis” [Mesh] OR “Bone Resorption” [Mesh] OR “Osteoclasts” [Mesh] OR “Osteoblasts” [Mesh].

These concepts were combined using the Boolean operator “AND.” The search was supplemented with free-text terms such as “bone health,” “bone mineral density,” “osteogenic differentiation,” and “osteoclastogenesis” to capture additional relevant studies. The search was limited to articles published from database inception until May 2025 and to those written in English. The detailed PubMed search strategy is provided as follows: (“Polyphenols” [Mesh] OR “Carotenoids” [Mesh] OR “Saponins” [Mesh] OR “Phytochemicals” [Mesh]) AND (“Osteoporosis” [Mesh] OR “Osteogenesis” [Mesh] OR “Bone Resorption” [Mesh] OR “Osteoclasts” [Mesh] OR “Osteoblasts” [Mesh] OR “bone health” OR “bone mineral density”).

The retrieved records were initially screened by title and abstract. Studies that investigated the molecular mechanisms, efficacy, or biological effects of the specified bioactives on bone metabolism or OP models were selected for full-text review. The full texts of these articles were then assessed for eligibility based on the inclusion and exclusion criteria. The reference lists of key review articles were also manually examined to identify any additional relevant publications that might have been missed in the electronic search.

3 Pathogenesis of OP

Bone is a highly dynamic mineralised connective tissue whose structural integrity and functional capacity rely on a tight functional coupling between the mineralised organic matrix and its resident, lineage-committed cells (25). Skeletal homeostasis is maintained through a balance between osteoblast-mediated bone formation and osteoclast-mediated resorption. This critical balance is supplied by osteoprogenitor cells derived from bone marrow mesenchymal stem cells (BM-MSCs) (26).

3.1 Main pathways of bone formation

Osteoblasts drive bone matrix synthesis and subsequent mineralisation, with tissue-non-specific alkaline phosphatase (ALP) and osteocalcin (OCN) serving as key functional biomarkers of osteogenic activity (27, 28). The transcription factors runt-related transcription factor 2 (Runx2) and osterix act as master regulators that initiate and stabilize osteoblastic commitment of BM-MSCs, while preserving their self-renewal and multilineage potential—essential for lifelong bone remodeling and repair (29, 30). Osteoblast differentiation and function are regulated by evolutionarily conserved signaling pathways, most notably the bone morphogenetic protein (BMP) and canonical Wnt/β-catenin cascades (29, 31). These pathways converge on Runx2 and osterix to ensure coordinated expression of bone matrix proteins and orchestrated mineralisation (17).

3.1.1 BMP pathway

BMP signaling centers on two converging arms: a canonical route in which activated type-I receptors phosphorylate Smad1/5/8, forming a Smad4-bound trimer that translocates to the nucleus and, with Runx2/Osterix, switches on osteogenic genes (OCN, ALP); and a non-canonical arm that engages p38 and extracellular signal-regulated kinase (ERK) to drive MSC proliferation and osteoblast survival. Together they commit MSCs to the osteoblastic lineage, hasten maturation and promote matrix mineralisation (32).

3.1.2 Wnt/β-catenin pathway

Wnt/β-catenin signaling is the master anabolic pathway for bone formation: it blocks GSK-3β-driven β-catenin degradation, allowing β-catenin to accumulate, enter the nucleus and partner with Runx2/Osterix to switch on osteogenic genes (OCN, ALP, and COL1A1) while repressing adipogenic fate, thereby boosting matrix production and mineralisation to sustain skeletal development and post-natal bone homeostasis (33, 34).

3.1.3 Phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt)/mTOR axis

The PI3K/Akt/mTOR axis is a master regulator of skeletal homeostasis. Akt-driven signaling steers BM-MSCs into osteoblasts, amplifying Runx2, Osterix, ALP and OCN expression, while boosting proliferation, matrix output and mineralisation. Simultaneously, it curbs osteoclastogenesis by dampening NF-κB/mitogen-activated protein kinase (MAPK) cues, raising OPG and lowering RANKL, thereby restraining resorption. mTOR-dependent autophagy shields osteoblasts from oxidative stress and apoptosis under high-glucose insults, and cross-talk with AMPK fine-tunes the whole network to preserve bone mass (35, 36).

3.2 Main pathways of bone resorption

In contrast to the anabolic function of osteoblasts, multinucleated osteoclasts mediate bone resorption through focal dissolution of the mineralised matrix. Excessive osteoclastic activity is a primary mechanism underlying net bone loss. Mature osteoclasts attach to the bone surface and establish a sealed microenvironment into which they secrete protons to solubilise hydroxyapatite, along with CTSK and matrix metalloproteinases that degrade the organic component of bone (37–39).

3.2.1 RANKL/RANK/OPG axis

Osteoclast differentiation, activity, and survival are predominantly regulated by RANKL–receptor activator of nuclear factor-κB (RANK)–OPG axis and macrophage colony-stimulating factor (37). Osteoblast-lineage cells produce both membrane-bound and soluble RANKL. Binding of RANKL to RANK on osteoclast precursors promotes their fusion, activation, and extended survival (40). Concurrently, osteoblasts secrete OPG, a decoy receptor that competitively binds RANKL, thereby inhibiting osteoclastogenesis (37). RANKL–RANK signaling further enhances bone resorption by stimulating the production of pro-inflammatory cytokines—such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and IL-7 (41, 42)—and by upregulating key transcription factors including c-Fos and nuclear factor of activated T cells c1 (NFATc1), which are central to terminal osteoclast differentiation (43, 44). The RANKL/OPG ratio serves as a critical molecular regulator determining the overall rate of bone turnover (1). Osteoblast-lineage cells and osteoclasts engage in continuous bidirectional communication, which calibrates the rate and extent of bone remodeling. This coupling represents a fundamental mechanism in the maintenance of skeletal homeostasis (1, 40, 45). When osteoclastic resorption persistently exceeds osteoblastic bone formation, a cumulative negative balance develops, leading to the initiation and progression of OP (46, 47).

3.3 Disruption of homeostasis in OP: key pathological processes

Disruption of skeletal homeostasis is driven by three interrelated pathological processes: aging-related microenvironmental alterations, defective autophagy, and dysregulated apoptosis. Firstly, with advancing age, senescent bone marrow-derived BM-MSCs accumulate and acquire a senescence-associated secretory phenotype (SASP)—a pro-inflammatory secretome marked by the elevated release of IL-6, IL-1β, and TNF-α (48). SASP not only intrinsically impairs osteogenic differentiation but also acts in a paracrine manner to NF-κB signaling in adjacent healthy BM-MSCs. This induces “secondary senescence,” perpetuating a self-reinforcing cycle of impaired bone formation that contributes to age-related OP (48). Autophagic activity is significantly diminished in osteoblasts and BM-MSCs from osteoporotic patients. This reduction compromises the clearance of dysfunctional organelles and extracellular matrix components, thereby amplifying catabolic signaling and accelerating bone loss (49). Furthermore, chronic NF-κB activation and elevated RANKL levels create a pro-apoptotic microenvironment: osteoblast survival is compromised, while caspase-mediated osteoclast apoptosis is suppressed (50). The resulting “double hit”—comprising attenuated bone formation and sustained resorption—severely disrupts remodeling equilibrium and culminates in net bone loss (51–53).

3.4 The gut-bone axis

The “gut–bone axis” has recently emerged as a pivotal regulator of skeletal metabolism. Intestinal microbiota and their bioactive metabolites engage in systemic cross-talk that indirectly modulates bone remodeling (54). By enhancing systemic anti-inflammatory pathways, they mitigate pro-inflammatory signaling within the bone microenvironment, thereby helping to preserve skeletal integrity (55). This paradigm broadens current understanding of metabolic bone regulation and identifies modulation of microbial composition and function as a promising therapeutic strategy for OP (56) (Figure 1).

Figure 1

The imbalance between bone formation and bone resorption leads to OP. Bone metabolic homeostasis is fundamental to skeletal health. Osteoblast activity is principally regulated by the BMP and Wnt/β-catenin pathways. These signaling cascades converge to activate key transcription factors—such as Runx2 and osterix—which ultimately coordinate bone matrix synthesis and mineralisation. Osteoclastogenesis is primarily governed by the RANKL–RANK–OPG axis: RANKL, secreted by osteoblasts, to RANK on osteoclast precursors promotes osteoclast differentiation and survival. OPG, also produced by osteoblasts, acts as a decoy receptor that competitively binds RANKL, thereby inhibiting osteoclast formation and activity.Disruption of bone metabolic equilibrium is implicated in multiple pathological processes. An elevated RANKL/OPG ratio—a key indicator of bone turnover—drives bone loss. Furthermore, senescent BM-MSCs adopt a SASP with pro-inflammatory properties. This inflammatory microenvironment not only directly impairs osteogenic differentiation but also disrupts fundamental physiological processes such as apoptosis. Additionally, gut microbiota and their metabolites indirectly modulate bone remodeling via the gut–bone axis, further linking systemic and local regulation of bone metabolism.

Diagram illustrating bone homeostasis and osteoporosis. On the left, bone formation and resorption are balanced, with Runx2, Osterix, Wnt/β-catenin, and BMP driving formation through osteoblasts while RANKL from osteoclasts resorbs bone. The right shows osteoporosis, where bone formation is less than resorption due to OPG/RANKL imbalance, apoptosis, inflammatory cytokines, and SASP. A bone graphic connects both processes.

4 The anti-OP effects of plant-derived bioactives 4.1 The therapeutic potential of polyphenols in osteoporosis: antioxidant, anti-inflammatory, and pro-osteogenic actions

Polyphenols, which are natural bioactive compounds found in various medicinal plants, aromatic herbs, foods, and beverages, possess diverse biological properties, including antioxidant, anti-inflammatory, anti-insulin resistance, and osteogenic activities. They beneficially modulate bone metabolism by attenuating bone resorption, preserving bone density, and inhibiting osteoclast differentiation. Moreover, polyphenols can concurrently target multiple molecular markers within various signaling pathways (22, 57). Beyond these actions, polyphenols induce osteoclast apoptosis and inhibit RANKL-induced osteoclastogenesis and reactive oxygen species (ROS) production (58, 59). They also stimulate the synthesis of bone morphogenetic protein 2 (BMP-2) and reduce the secretion of bone-resorptive cytokines such as TNF-α and IL-6 (60, 61).

4.1.1 Modulation of bone metabolism

Polyphenols possess antioxidant, anti-inflammatory, and bone metabolism-regulating properties. Their combination with hydrogels can enhance bone tissue repair (62). Such combinations not only regulate local bone metabolism and oxidative stress but also provide mechanical support and tissue adhesion, thereby facilitating osteoporotic bone regeneration (62). Although plant-derived polyphenols inhibit osteoclast differentiation by reducing ROS generation, their bioavailability is limited due to poor intestinal absorption (63). In contrast, 4-hydroxyphenylacetic acid (4-HPA)—a microbial metabolite of polyphenols produced by the gut microbiota—effectively suppresses osteoclast differentiation and function. It downregulates key osteoclast-specific genes, including NFATc1, vacuolar-type proton ATPase subunit d2 (Atp6v0d2), matrix metallopeptidase 9, CTSK, acid phosphatase 5, and c-Fos (63). The underlying mechanism involves 4-HPA-mediated activation of nuclear factor erythroid 2-related factor 2 (Nrf2), which reduces ROS accumulation and consequently inhibits the NF-κB and MAPK signaling pathways (63). Furthermore, polyphenols enhance the expression of osteogenic markers such as Runx2, ALP, OCN, and osterix. They also inhibit the secretion of cytokines and interleukins from senescent BM-MSCs, which otherwise promote senescence in young BM-MSCs. By preserving the pool of young BM-MSCs—which are essential for osteoblast differentiation and new bone formation—polyphenols play a crucial role in mitigating OP and maintaining skeletal integrity (48).

4.1.2 Resveratrol: a prototypical polyphenol with extensive evidence

Resveratrol has been one of the most extensively investigated natural polyphenols in recent years. It exerts multi-target effects and demonstrates considerable therapeutic potential in delaying aging, cardioprotection, and anticancer activities (64). Dietary resveratrol at appropriate doses is generally regarded as clinically safe and non-toxic (65). Numerous studies indicate its efficacy against various forms of OP, including those associated with chronic kidney disease (66, 67), breast cancer treatment (68), high-altitude hypoxia (69), and androgen deficiency (70). Furthermore, Qu et al. (71) reported that resveratrol can prevent or reverse rosiglitazone-induced OP in patients with type 2 diabetes (71). The combination of resveratrol and equol may favorably modulate bone turnover markers and BMD, suggesting a potential strategy for preventing age-related bone loss in post-menopausal women (72). Resveratrol significantly enhances the proliferative capacity of BM-MSCs in osteoporotic patients and plays a crucial role in regulating their pluripotency, osteogenic differentiation, and adipogenic differentiation—mechanisms integral to its anti-osteoporotic effects (73). Along with other polyphenols such as curcumin and quercetin, resveratrol positively modulates bone metabolism and osteoclast-related disorders (74). Additional studies indicated that resveratrol can counteract iron-overload-induced OP via its antioxidant properties (75). Nevertheless, its efficacy is not universal across all forms of OP. For instance, Zama et al. observed that it did not enhance implant-related bone repair in ovariectomised rats with OP (76).

4.1.3 Modulation of the gut-bone axis

Dysbiosis of the gut microbiota represents a promising early clinical indicator for an elevated risk of OP (77). Polyphenols act as modulators and inducers within the gut–bone–immune axis by enhancing the abundance and functional activity of gut microbial communities (77). The metabolic profile of resveratrol may serve as a potential therapeutic biomarker for evaluating both its efficacy and associated changes in gut microbiota composition (78). Tea-polyphenol intervention also reshapes the gut microbial community and the serum metabolite profile in osteoporotic mice (79). Furthermore, polyphenols promote the proliferation of probiotic species in the gut, which contributes to reduced bone resorption and increased BMD, thereby exerting anti-osteoporotic effects (80).

4.1.4 Dietary sources and clinical translation

A diet rich in polyphenols modulates the gut and oral microbiota, influencing the gut–bone axis and supporting the potential of resveratrol as both a preventive and adjunctive therapeutic agent for primary and secondary OP (78). Flavonoids, a subclass of polyphenols, are recommended for bone health maintenance due to their antioxidant, anti-inflammatory, and osteogenic properties. Higher dietary intake of flavones and flavanones is significantly associated with reduced bone loss at the femoral neck, though not in the lumbar spine (81). Therapeutically, polyphenols are metabolized into bioactive compounds that inhibit inflammatory factors, enhance gut barrier integrity, and modulate immune responses, collectively suppressing bone loss and osteoclastogenesis (82). Resveratrol, in particular, holds considerable promise as a dietary supplement or pharmaceutical agent for the clinical management of OP (83). For post-menopausal women without overt OP, twice-daily supplementation with 75 mg of resveratrol may attenuate bone loss in fracture-prone sites such as the lumbar spine and femoral neck (84). Moreover, several clinical trials have demonstrated that higher polyphenol intake raises circulating OCN and ALP and ameliorates osteopenia in post-menopausal women (85–87). Additionally, a study by Asfha et al. (88) demonstrated that teff (an Ethiopian grain)-derived biscuits containing eight flavonoid polyphenols may prevent OP through RANKL binding and interaction with key osteoclastic signaling sites (88). Freeze-dried strawberry powder, rich in polyphenols, has been shown to elevate levels of insulin-like growth factor-1, a bone-forming hormone, in post-menopausal women with pre-hypertension or stage 1 hypertension (89). Trifolirhizin also emerges as a novel candidate for the treatment of senile and post-menopausal OP (90).

4.2 Carotenoids as potent antioxidants and bone-protective agents

ROS-induced oxidative stress is closely associated with an increased risk of OP. Certain dietary antioxidants can help mitigate this oxidative damage (91). Notably, studies have shown that plasma retinol and all detected carotenoid levels are consistently lower in women with OP compared to healthy controls (92, 93). As potent antioxidants, carotenoids also serve as a dietary source of vitamin A and are believed to play a crucial role in disease prevention and health maintenance (94).

4.2.1 Modulation of bone metabolism

Carotenoids directly engage with, and modulate, bone-metabolic homeostasis through several routes. Lycopene is among the most intensively studied. Over two decades ago, Kim et al. first reported that lycopene stimulates the proliferation and differentiation of human osteoblasts, implying its potential role in OP prevention (95). Subsequent studies in ovariectomised rats show that lycopene preserves osteoblast function, restrains resorption and, by curbing excessive turnover, restores both mechanical strength and trabecular microarchitecture (96, 97). A clinical study further demonstrated that lycopene supplementation significantly reduces oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in post-menopausal women, thereby lowering bone turnover rates and ultimately reducing the incidence of OP (98). Moreover, combined lycopene and genistein treatment mitigates glucocorticoid-induced OP (99, 100). Taken together, lycopene supplementation represents a promising nutritional strategy for OP prevention, especially in post-menopausal women.

Other carotenoids also contribute to bone metabolism regulation. Tao et al. found that astaxanthin intervention significantly reversed the inhibitory effect of palmitate on osteogenic differentiation and the upregulation of osteoclast differentiation (101). At doses of 5 or 10 mg/kg, crocin not only prevents histopathological bone deterioration but also demonstrates a dual regulatory effect on bone turnover by elevating formation markers (ALP, OCN) and suppressing resorption markers (tartrate-resistant acid phosphatase and type I collagen cross-linked C-telopeptide) (102). Lutein, another carotenoid, effectively preserves bone mass by modulating both bone resorption and formation, showing potential for the prevention of disuse OP (103).

Carotenoids were also protective against 4-year bone density loss at the trochanter in men and at the lumbar spine in women (104). A Mendelian randomization study indicated that genetically predicted serum β-carotene levels are associated with increased BMD and a reduced risk of OP (105). Although β-carotene may contribute to higher bone density and a lower risk of OP and fractures, these effects may vary by sex and ethnicity (23).

4.2.2 Antioxidant effects and bone health

Unlike β-carotene, lycopene lacks vitamin-A activity but is a powerful antioxidant that lowers the risk of age-related chronic disease (92). Clinical reports confirm that dietary antioxidants such as lycopene can decrease oxidative stress and bone turnover markers in post-menopausal women, contributing to a reduced risk of OP (91). Similarly, crocin reduces oxidative stress in distal femoral epiphyseal tissue and enhances the longitudinal and vertical mechanical properties of the femur, thereby improving metabolic syndrome-induced OP (102). The antioxidant properties of carotenoids may counteract mechanisms underlying OP related to cachexia (106).

The collective intake of antioxidant nutrients appears to lower the likelihood of OP in women (107). Dietary consumption of β-carotene and β-cryptoxanthin may benefit bone health (108), population-based studies indicate that, in combination with vitamin C, they are associated with a reduced risk of OP (108–110). And higher intakes of total carotenoids and lycopene are associated with reduced hip-fracture risk in long-term follow-up (111). In the European Prospective Investigation into Cancer and Nutrition (EPIC)–Norfolk cohort, dietary carotenoid intake was associated with improved bone health in both men and women, confirming that both intake and plasma concentrations of specific carotenoids correlate with BMD status and the risk of osteoporotic fractures (112). A prospective cohort study further demonstrated that antioxidant carotenoids—particularly β-cryptoxanthin and β-carotene—are inversely correlated with changes in radial BMD among post-menopausal women (113). Similarly, a study by Li-li Sun et al. indicated that dietary antioxidant nutrients, including β-carotene, are associated with a reduced risk of hip fracture among older Chinese adults (114). Total dietary carotenoids, as well as specific types such as α-carotene, β-carotene, and lutein/zeaxanthin, were negatively correlated with hip fracture risk. Furthermore, analysis of the National Health and Nutrition Examination Survey indicates that higher intakes of β-carotene, β-cryptoxanthin, lutein, and zeaxanthin are associated with reduced OP risk (115). In summary, dietary carotenoid intake is of considerable clinical relevance, as these antioxidants can reduce bone resorption, enhance BMD, and thereby help lower the risk of OP.

4.3 Regulatory effects of saponins on bone metabolism

Saponins are a class of natural compounds abundantly present in traditional Chinese medicines and have garnered significant interest for their potential role in the management of OP. Two decades ago, Nian et al. reported that anemarrhena steroidal saponins could prevent bone loss in ovariectomised rats (116). Subsequent research has further established the importance of saponins in the prevention and treatment of OP, with various types of saponins likely acting through shared mechanisms.

4.3.1 Modulation of bone metabolism

On one hand, ginsenoside Rg3 influences osteoclast differentiation (117). Yanhuai Ma et al. observed that ginsenosides inhibit osteoclastogenesis and reduce bone loss in castrated mice, suggesting therapeutic potential for male OP (118). On the other hand, ginsenosides also regulate osteogenesis, offering novel targets and strategies for OP treatment (119). For instance, ginsenoside Rb1 promotes osteoblast differentiation and may hinder OP progression via modulation of the aryl hydrocarbon receptor (AHR)/Proline/arginine-rich end leucine-rich repeat protein (PRELP)/NF-κB axis (120). Ginsenoside Rb2 exhibits anti-osteoporotic effects by mitigating oxidative damage and osteoclast-related cytokines during bone formation (121). Network analysis revealed that ginsenoside Rh2 exhibits strong binding affinity to four target proteins (IL1β, TNF, IFNG, and NFKBIA), underscoring its relevance in OP treatment, with osteoblast differentiation emerging as a key signaling pathway (122). Moreover, ginsenoside Rg3 has been shown to alleviate aluminum-induced OP in rats by modulating oxidative stress, bone metabolism, and osteogenic activity (123, 124). Triterpenoid saponins from Pimpinella candolleana have been shown to promote osteogenic differentiation and improve trabecular bone structure, with efficacy comparable to that of alendronate (125). Furthermore, notoginsenosides inhibit radiation-induced OP by modulating the balance between bone formation and resorption (126).

4.3.2 Anti-OP effects: preclinical evidence

The most extensively studied saponins are ginsenosides, which exert significant effects on osteoblasts, osteoclasts, and chondrocytes. They have demonstrated efficacy in increasing BMD and alleviating symptoms of osteoarthritis. Mechanistically, ginsenosides modulate cell differentiation, activity, and key signaling molecules such as MAPKs (127). Studies indicate that ginsenosides are beneficial across multiple forms of OP, including glucocorticoid-induced (119), castration-induced (118), ovariectomy-induced (128), and aluminum-induced models (123). Using network pharmacology, Zhang et al. identified five core gene clusters—STAT3, PIK3R1, VEGFA, JAK2, and MAP2K1—as potential therapeutic targets of ginsenosides in OP (129). It is noteworthy, however, that ginsenoside Rb1 did not prevent osteoporotic bone loss in ovariectomised rats (130). In summary, ginsenosides provide a robust theoretical foundation for future clinical applications in the treatment of OP (131).

Dipsacus asperoides is a traditional Chinese medicine with a history of over 2000 years in China. It is widely recognized for its ability to nourish the liver and kidneys, strengthen bones and muscles, and promote fracture healing. It is also commonly used in the treatment of OP, owing to the anti-osteoporotic effects of its saponin constituents (132). Guan et al. (133) isolated saponins from Dipsacus asperoides present in the absorbed components of the Xian-Ling-Gu-Bao capsule in the bloodstream and evaluated their anti-osteoporotic efficacy in a zebrafish model (133). The results demonstrated that these saponins could reverse prednisolone-induced reductions in bone mineralisation, confirming that they constitute the material basis for the pharmacological effects of the Xian-Ling-Gu-Bao capsule (133). Similarly, holothurian saponin A and holothurian glycoside A can increase bone density and bone deposition rates, reverse trabecular and bone marrow stromal loss, and thereby ameliorate ovariectomy-induced OP (134). Other saponins, such as Ziyu glycoside II (135), notoginsenosides (136), and soy saponins (137), have also demonstrated efficacy in alleviating OP in ovariectomised mice, making them promising natural candidates for the treatment of post-menopausal OP. Furthermore, astragaloside ASI-IV has been found to inhibit iron-load-induced bone loss in mice and protect against abnormal differentiation of BM-MSCs under iron overload conditions by regulating iron homeostasis and metabolism (138). Tu-bei-mu-gan-jia (tubeimoside I) shows protective effects against bone loss in rats with type 2 diabetes-induced OP (139). Anemarrhena saponin BII alleviates deterioration of the tibial microstructure in diabetic rats and reduces hyperglycaemia-induced apoptosis of primary rat calvarial osteoblasts in a dose-dependent manner (140) (Table 1).

Table 1

Plant-derived food bioactives and their anti-osteoporosis effects.

Plant-derived food bioactives	Effects on OP	Representative substances
Polyphenols	•Treating or preventing OP: • Chronic kidney disease-induced OP • Secondary OP in breast cancer patients • OP induced by high—altitude hypoxia • OP induced by male gonadal dysfunction • Rosiglitazone-induced OP in patients with type 2 diabetes • Senile and post-menopausal OP • Iron-overload-induced OP • Estrogen deficiency-induced OP •Antioxidant properties •Anti-inflammatory •Enhancing the abundance and functional activity of gut microbial communities	• Resveratrol • Curcumin • Quercetin • Flavonoids • Trifolirhizin • Polyphenol-rich extracts from Calendula officinalis (marigold) flowers • Danshensu • Polyphenols from areca nut seeds
Carotenoids	•Anti-OP effects: • Glucocorticoid-induced OP • Post-menopausal OP • Senile OP • OP related to cachexia • Disuse OP •Antioxidant properties •Promoting bone formation •Inhibiting bone resorption •Increasing BMD	• Lycopene • Astaxanthin • Crocin • Lutein • β-carotene • β-cryptoxanthin
Saponins	•Anti-OP effects: • Glucocorticoid-induced OP • Castration-induced OP • Aluminum-induced OP • Post-menopausal OP • Radiation-induced OP • Iron-load-induced • Type 2 diabetes-induced OP •Increasing BMD •Promoting bone formation •Inhibiting bone resorption •Regulating gut microbiota •Reducing inflammation	• Ginsenosides • Dipsacus asperoides • Triterpenoid saponins from P. candolleana • Holothurian saponin A • Ziyu glycoside II • Notoginsenosides • Soy saponins • Astragaloside • Tubeimoside I • Fenugreek-derived steroidal saponins

5 Regulatory mechanisms of major plant-derived bioactives on OP 5.1 Molecular mechanisms of polyphenols in regulating OP

The mechanisms by which phenolic compounds affect bone metabolism are complex. These mechanisms include stimulating the differentiation, maturation, and proliferation of osteoblasts through estrogen receptors, as well as activating key signaling pathways such as ERK 1/2 (141), p38 MAPK (142), and Wnt (143).

5.1.1 Resveratrol exerts significant beneficial effects through multiple targets and pathways

Resveratrol regulates the balance between bone formation and resorption, promoting osteoblast differentiation via the PI3K/Akt, SIRT1, AMP-activated protein kinase (AMPK), and GATA binding protein 1 pathways while inhibiting osteoclastogenesis by suppressing MAPK and tumor necrosis factor receptor-associated factor 6/transforming growth factor-β-activated kinase 1(TRAF6/TAK1) signaling. This dual action helps maintain bone metabolic homeostasis and confers a bone-protective effect (67). For example, in a model of spinal cord injury-induced OP, Zhong (144) demonstrated that resveratrol enhances the bone-protective efficacy of calcium supplementation by modulating the SIRT1/forkhead box O3a (FOXO3a) pathway along with osteoblast and osteoclast activity. They proposed that the combination of resveratrol and calcium may represent an effective therapeutic strategy for the treatment of spinal cord injury-induced OP (144). At the molecular level, resveratrol inhibits osteoblast apoptosis by regulating proteins such as TNF, IL-6, and caspase-3, thereby promoting osteoblast formation (145). Furthermore, it counteracts the age-related decline in bone formation by improving osteogenic function in senescent BM-MSCs, an effect mediated through the enhancement of mitochondrial function via mitochondrial serine protease (146).

Antioxidant and anti-inflammatory mechanisms. Resveratrol mitigates oxidative stress and inflammation-induced bone loss through activation of the Hippo signaling pathway/Yes-associated protein (Hippo/YAP) and the Nrf2 pathway, as well as inhibition of the ROS/hypoxia-inducible factor-1α (ROS/HIF-1α) and nicotinamide adenine dinucleotide phosphate oxidase 4(Nox4)/NF-κB pathways (67, 147). Moreover, resveratrol enhances cellular resistance to oxidative damage and suppresses osteoclastogenesis by upregulating FoxO1 transcriptional activity via inhibition of the PI3K/Akt signaling pathway (148).

Targeted regulation in response to specific stimuli. Under hypoxic conditions, resveratrol enhances the osteogenic differentiation and mineralisation of BM-MSCs and upregulates osteogenic markers—including RUNX2, ALP, OCN, and OPN—through inhibition of the ROS/HIF-1α pathway (69). Notably, it ameliorates androgen-deficient bone loss by reestablishing the balance between RANK and OPG (70). Furthermore, resveratrol counteracts estrogen deficiency-induced OP through multiple mechanisms: it elevates miR-92b-3p expression to attenuate the NADPH oxidase 4/NF-κB pathway (149), inhibits miR-338-3p to upregulate Runx2 in osteoblasts (150), and facilitates osteoblast differentiation via SIRT1–NF-κB signaling (151).

5.1.2 Diverse bone-protective mechanisms of other polyphenols

Activating Wnt/β-catenin signaling to promote osteogenesis. Polyphenol-rich extracts from Calendula officinalis (marigold) flowers (27) and anthocyanin-rich compounds derived from Hibiscus sabdariffa (hibiscus) petals (152) promote osteogenic differentiation and ameliorate osteoporotic bone loss by inhibiting glycogen synthase kinase 3β and subsequently activating β-catenin (27, 152). Berry polyphenols—anthocyanins in particular—also support bone health through antioxidant and anti-resorptive mechanisms (153). Additionally, danshensu attenuates bone marrow adiposity via the KLF15/peroxisome proliferator-activated receptor γ2(PPARγ2)/FOXO3a/Wnt axis, thereby counteracting glucocorticoid-induced OP (154).

Inhibiting osteoclastogenesis to suppress bone resorption. Trifolirhizin, a natural flavonoid glycoside, suppresses osteoclast differentiation and bone resorption through downregulation of key osteoclastogenic marker genes, signaling mediators, and bone resorption-associated proteins, alongside an increase in the serum OPG/RANKL ratio (90).

Modulating the Gut–Bone Axis and Bone Marrow Environment. Polyphenols from areca nut seeds enhance lysozyme expression by preserving Paneth cell populations, which correlates with gut microbiota modulation and amelioration of OP via control of inflammatory responses (155). Similarly, danshensu targets the adipose–bone metabolic crosstalk, reducing bone marrow fat accumulation and supporting bone integrity (154) (Figure 2).

Figure 2

Mechanisms of polyphenols in OP prevention. Resveratrol, a polyphenol, promotes osteogenesis by activating PI3K/Akt, SIRT1, AMPK and Wnt pathways, and inhibits osteoclast differentiation and bone resorption by suppressing MAPK/TRAF6/TAK1 and lowering the RANKL/OPG ratio. It also inhibits ROS/HIF-1α and Nox4/NF-κB to reduce oxidative stress and bone loss. Resveratrol can inhibit miR-338-3p to upregulate the expression of runt-related transcription factor 2 in human osteoblasts, promoting osteogenesis, and upregulate miR-92b-3p to weaken the Nox4/NF-κB pathway, inhibiting bone resorption. Danshensu affects fat-bone balance and reduces marrow fat accumulation. Betel nut polyphenols regulate gut microbiota and improve osteoporosis by controlling inflammatory responses.

Diagram illustrating the effects of polyphenols on bone cells. Polyphenols activate osteoblasts via pathways like Wnt/β-catenin and inhibit osteoclasts through mechanisms involving NOX4/NF-κB and RANKL/OPG. Additional impacts include adipose-bone balance, gut microbiota modulation, and miRNA regulation, affecting miR-338-3p and miR-92b-3p.

5.2 Carotenoids mediate anti-osteoporotic effects through diverse molecular mechanisms

Lycopene mediates anti-osteoporotic activity through multiple mechanisms, with key pathways including the following: lycopene promotes the osteogenic differentiation of human BM-MSCs via the estrogen receptor 1 (ESR1)/PI3K/Akt signaling pathway, thereby counteracting bone loss and providing a molecular basis for its potential use in OP treatment (156). It also suppresses excessive ROS generation in the bone marrow and BM-MSCs of ovariectomised rats, reducing adipogenesis and favoring osteogenesis during bone remodeling (157). Furthermore, lycopene enhances osteoblastogenesis and inhibits adipogenesis by modulating the oxidative stress-driven FoxO1/PPARγ pathway, ameliorating osteoporotic bone loss (157). Lycopene may also mitigate age-related bone deterioration by inhibiting oxidative stress, cellular senescence, and the SASP, supporting its role in the management of senile OP (158). Additionally, the combination of lycopene with genistein—particularly when co-administered—may counteract glucocorticoid-induced adverse effects through complementary molecular pathways such as Wnt/β-catenin and Nrf2, thereby stimulating bone formation, reducing bone resorption, and improving bone architecture (100).

Astaxanthin may inhibit palmitate-induced bone loss via its antioxidant properties, mediated through the SIRT1 signaling pathway (101). It also specifically targets osteoclasts: Hwang et al. demonstrated that astaxanthin suppresses osteoclast formation by regulating the expression of NFATc1, dendritic cell-specific transmembrane protein, tartrate-resistant acid phosphatase, and CTSK, without exerting cytotoxic effects on bone marrow-derived macrophages, indicating therapeutic potential for post-menopausal OP (159). Lutein plays a key role in protecting ovariectomised rats from OP through activation of Nrf2 and downregulation of inflammatory responses and osteoclast-specific markers, including NFATc1 (160).

5.3 Molecular mechanisms of saponins in OP

The molecular mechanisms through which saponins exert their preventive and therapeutic effects on OP primarily encompass the following aspects:

5.3.1 PI3K/Akt/mTOR signaling pathway

Ginsenosides may modulate osteogenesis by mediating the expression of the G protein-coupled estrogen receptor, which in turn modulates Akt phosphorylation within the PI3K/Akt pathway (119). Zhang et al. also reported that ginsenoside Rg3 attenuates OP induced by ovariectomy via the AMPK/mTOR signaling pathway (161). Similarly, dipsacoside VI promotes osteogenic differentiation of bone marrow stromal cells in ovariectomised rats through the PI3K/Akt signaling pathway (162). Furthermore, notoginsenosides have been shown to regulate the expression of angiogenesis-related factors via the PI3K/Akt/mTOR pathway, thereby facilitating the healing of osteoporotic fractures in ovariectomised rats (163). Additionally, anemarrhena saponin BII activates autophagy in osteoblasts by inhibiting the mTOR/NF-κB pathway, thus ameliorating high glucose-induced oxidative stress and apoptosis (140).

5.3.2 BMP-2/BMPR1A/Runx2 axis

Zhang et al. (164) demonstrated that ginsenoside Rg3 mitigates glucocorticoid-induced OP by regulating the BMP-2/BMPR1A/Runx2 signaling pathway (164). Astragaloside IV also promotes osteogenic differentiation of BM-MSCs through the miR-21/nerve growth factor/BMP2/Runx2 pathway (165). Moreover, soyasaponin Bb, present in peanut sprouts, enhances the expression of the osteogenic transcription factor Runx2 and ALP, showing potential for the prevention of bone disorders, including OP (166).

5.3.3 RANKL/RANK/OPG signaling pathway

Triterpenoid saponins from P. candolleana activate the P38/c-Jun N-terminal kinase (JNK) MAPK pathway and upregulate the OPG/RANKL axis, thereby modulating bone metabolism and stimulating osteogenesis (125). Fenugreek-derived steroidal saponins inhibit the colony-stimulating factor 1 (CSF-1)/CSF-1R-induced phosphorylation signaling pathway in both osteoclasts and osteoblasts. This results in suppression of RANK expression in osteoclasts and reduction of ROS generation in osteoblasts. Consequently, the ratio of RANKL to OPG is decreased, leading to diminished survival, proliferation, and differentiation of osteoclasts (167).

5.3.4 MAPK signaling pathway

Ginsenosides modulate osteoclast differentiation through the c-Fms-mediated MAPK and PI3K signaling axis (129). Platycodon saponin D, the most abundant and pharmacologically active triterpenoid saponin in Platycodon grandiflorum, inhibits RANKL-induced activation of NF-κB, ERK, and p38 MAPK, ultimately suppressing osteoclast differentiation (168). Similarly, bupleurum saponin A inhibits osteoclastogenesis by attenuating RANKL-induced activation of p38, ERK, JNK, and NF-κB, demonstrating potential as a novel therapeutic agent for OP (169).

5.3.5 NF-κB signaling pathway

Studies show that ginsenosides exert anti-osteoporotic effects chiefly by suppressing osteoclastogenesis through the NF-κB/MAPK signaling pathway (117, 118, 170). Astragaloside IV may inhibit macrophage senescence and stimulate the osteogenic differentiation of BM-MSCs by modulating the stimulator of interferon genes/NF-κB pathway, thereby exerting anti-osteoporotic effects. Consequently, astragaloside IV shows promise as a therapeutic candidate for the treatment of OP (171). In addition, holothurin A and echinoside A were found to significantly downregulate the expression of inhibitor of kappa B kinase, NF-κB, and phosphorylated NF-κB p65, and inhibit the expression of the osteoclastogenic transcription factors c-Fos and NFATc1 (134). Furthermore, tubeimoside I also ameliorates bone loss in rats with type 2 diabetic osteoporosis in the same manner (139).

5.3.6 Others

Ginsenoside Rc promotes bone formation in ovariectomised mice-induced OP in vivo and osteogenic differentiation in vitro via the Wnt/β-catenin signaling pathway (128). Another study has shown that ginsenoside Rg1 modulates pathways principally involved in retinol, fat, protein and lipid metabolism, a mechanism that may underlie its ability to counter glucocorticoid-induced osteoporosis (172). Astragaloside IV (AST-IV) can promote the differentiation of BM-MSCs, with glycogen synthase kinase 3β signaling pathway involved in its osteogenesis induction, and it accelerates cell differentiation by increasing the expression level of nerve growth factor (173). Ziyu Glycoside II can also alleviate bone loss in ovariectomised mice by reducing inflammation, regulating gut microbiota (including unclassified Muribaculaceae family and Dysgonomonas genus) and short-chain fatty acids (135). Hu et al. (136) found through ovariectomised mice that notoginsenosides can activate osteogenesis and angiogenesis, thereby increasing bone mass, indicating its potential role in the prevention and treatment of OP in post-menopausal women (136). Furthermore, a study has shown that asperosaponin VI restores expression of the anti-ferroptotic factor GPX4, thereby attenuating the ferroptotic pathology linked to diabetic osteoporosis and positioning it as a potential therapeutic agent for this complication (174) (Figure 3).

Figure 3

Molecular mechanisms of saponins in osteoporosis prevention. (SaponinsGinsenosides, Dipsacoside, notoginsenosides, Astragaloside IV, etc.) Reshape the balance of bone metabolism by promoting osteogenesis and inhibiting osteoclastogenesis, thereby treating osteoporosis. Saponins mainly promote osteogenesis through the PI3K/Akt/mTOR, BMP-2/Runx2 axis, Wnt/β-catenin and other signaling pathways, and inhibit osteoclast formation and reduce bone resorption through the RANKL/RANK/OPG, MAPK, NF-κB signaling pathways.

Diagram illustrating the molecular mechanisms of saponins in osteoporosis (OP). It shows saponins promoting osteogenesis through PI3K/Akt/mTOR, BMP-2/Runx2, and Wnt/β-catenin pathways, while inhibiting bone resorption by affecting osteoclasts via RANKL/RANK/OPG, NF-κB, and MAPK signaling paths. Below are images of bone structure affected by saponins, with examples like ginsenosides, dipsacoside, notoginsenosides, and astragaloside IV.

6 Influence of experimental models on evaluating bioactive efficacy: a comparative perspective

The preclinical evidence presented here derives largely from distinct animal models of OP, each recapitulating specific etiologies. A critical appraisal of how these model-specific pathophysiologies shape both the observed efficacy and the dominant mechanisms of plant-derived bioactives is essential if such findings are to be translated into targeted clinical contexts. Here we compare the two most widely used paradigms: the ovariectomy model, which mimics post-menopausal OP, and the glucocorticoid-induced model, representing secondary OP.

6.1 Pathophysiological dichotomy: ovariectomy model vs. glucocorticoid-induced models

The ovariectomy model is driven chiefly by estrogen deficiency, producing high-turnover bone loss in which osteoclastic resorption is markedly accelerated. Key molecular hallmarks include a significantly elevated RANKL/OPG ratio, enhanced NF-κB/MAPK signaling in osteoclast precursors and a pro-inflammatory microenvironment (175). By contrast, the glucocorticoid-induced model suppresses osteoblast activity directly and promotes apoptosis of osteoblasts and osteocytes, yielding a low-formation lesion (176). Although resorption may rise initially, the dominant defect is inhibition of anabolic pathways—principally the Wnt/β-catenin and BMP-2/Runx2 axes.

6.2 Consequences for bioactive efficacy and mechanism

The dichotomy described above determines how plant-derived bioactives manifest their polyvalent actions (Table 2). In the high-turnover ovariectomy model, compounds that curb resorption and inflammation are expected to excel: polyphenols such as resveratrol suppress RANKL signaling, NF-κB activation and osteoclast-specific transcription factors (NFATc1, c-Fos), thereby directly opposing the principal driver of estrogen-deficient bone loss, an effect consistent with the protection afforded by resveratrol and trifolirhizin in numerous ovariectomy studies (76, 84, 90). Likewise, saponins—ginsenoside Rb2 and fenugreek saponins, for example—that inhibit the RANKL/OPG/NF-κB/MAPK axis effectively blunt the exaggerated osteoclastogenesis of this model (118, 167). Conversely, the low-formation glucocorticoid-induced model favors agents that enhance anabolism and safeguard osteoblasts: the lycopene–genistein combination stimulates Wnt/β-catenin and Nrf2 signaling, directly countering the suppressed osteoblastogenesis and oxidative stress characteristic of glucocorticoid exposure (100), while saponins such as ginsenoside Rg3 and astragaloside IV, which up-regulate the BMP-2/Runx2 axis and promote marrow stromal-cell differentiation, offer a mechanistic remedy for impaired bone formation (164, 165). Divergent outcomes across models reinforce the point: ginsenoside Rb1, effective in a glucocorticoid-relevant AHR/PRELP/NF-κB pathway (120), is without benefit in ovariectomised rats (130), indicating that its action aligns with correction of glucocorticoid-induced dysregulation rather than estrogen-deficiency-driven hyper-resorption, and the deliberate tailoring of the lycopene–genistein combination to glucocorticoid-induced pathology underlines the need for model-guided selection of bioactives.

Table 2

Comparative analysis of principal OP models and their implications for the evaluation of plant-derived bioactives.

Feature	Ovariectomy model (post-menopausal OP)	Glucocorticoid-induced model (glucocorticoid-induced OP)
Primary induction	Surgical removal of ovaries (estrogen deficiency)	Administration of high-dose glucocorticoids
Core pathology	High bone turnover; Dominant increase in bone resorption	Low bone formation; Dominant suppression of osteoblast function
Key molecular hallmarks	↑RANKL/OPG ratio; ↑NF-κB/MAPK signaling in osteoclasts; Pro-inflammatory state	↓ Wnt/β-catenin signaling; ↓ BMP-2/Runx2 activity; ↑ Osteoblast/osteocyte apoptosis
Ideal for evaluating	Anti-resorptive and anti-inflammatory mechanisms	Anabolic (pro-osteogenic) and osteoblast/osteocyte-protective mechanisms
Relevant bioactives	• Polyphenols: Resveratrol, Trifolirhizin (inhibit RANKL/NF-κB) • Carotenoids: Astaxanthin, Lutein, lycopene • Saponins: Ginsenoside Rb2, Notoginsenosides, saponin A, Ziyu glycoside II, soy saponins, Fenugreek saponins (suppress osteoclastogenesis)	• Polyphenols: danshensu • Carotenoids: Lycopene + Genistein combo (activate Wnt/Nrf2) • Saponins: Ginsenoside Rg3 (enhances BMP-2/Runx2), Astragaloside IV (promotes osteogenesis)
Clinical translation context	Prevention and management of post-menopausal OP	Prevention of secondary osteoporosis in patients on long-term corticosteroid therapy

The inherent “model bias” within pre-clinical evidence is not a limitation, but rather a prerequisite for precision. Data from ovariectomised animals provide robust support for deploying anti-resorptive bioactives—selected polyphenols or saponins—in the management of post-menopausal OP, whereas glucocorticoid-based studies argue equally forcefully for pro-osteogenic formulations such as carotenoid–isoflavone combinations or specific saponins to forestall glucocorticoid-induced bone loss. Such a comparative framework will accelerate the formulation of etiology-specific nutraceutical strategies for OP.

7 Summary and outlook

This review summarizes the roles and mechanisms of dietary bioactive compounds—including polyphenols, carotenoids, and saponins—in the regulation of OP, with a particular emphasis on their core ability to modulate bone metabolism through coordinated multi-pathway actions. These bioactive substances counteract osteoporosis via a triple mechanism centered on antioxidant, anti-inflammatory, and bone metabolism-regulating properties. Polyphenols (e.g., resveratrol) activate the SIRT1/FOXO3a, Hippo/YAP, and Nrf2 pathways to enhance osteogenic differentiation, while inhibiting the ROS/HIF-1α and Nox4/NF-κB pathways to attenuate oxidative stress and inflammation (67, 69, 160). They also modulate the gut–bone axis (e.g., by elevating levels of the metabolite 4-HPA) and suppress osteoclast-related genes such as NFATc1 and CTSK (63). Carotenoids (e.g., lycopene and astaxanthin) promote osteogenesis through the ESR1/PI3K/Akt and FoxO1/PPARγ pathways (156, 157), inhibit adipogenesis via Nrf-2-mediated reduction of ROS accumulation, and impede osteoclast maturation by targeting markers including tartrate-resistant acid phosphatase and dendritic cell-specific transmembrane protein (100, 159). Saponins (e.g., ginsenosides and dipsacosides) regulate bone remodeling bidirectionally via pathways such as PI3K/Akt/mTOR, BMP-2/Runx2, and RANKL/OPG (163, 164, 167). They also inhibit NF-κB/MAPK signaling, leading to the downregulation of osteoclast-related transcription factors such as c-Fos and NFATc1 (170). Dietary bioactive compounds show considerable promise for clinical application in the prevention and treatment of osteoporosis. They offer notable safety advantages over synthetic pharmaceuticals, avoiding risks such as hypercalcaemia and thromboembolism associated with conventional treatments (e.g., bisphosphonates). Moreover, combination therapies may enhance efficacy: for example, resveratrol combined with calcium improves bone density in individuals with spinal cord injury, while lycopene and genistein act synergistically to ameliorate glucocorticoid-induced bone loss.

Promising pre-clinical findings for plant-derived bioactives must be set against a number of fundamental obstacles that presently hinder their direct translation to the clinic. First, poor systemic bioavailability markedly restricts the efficacy of many compounds—most polyphenols, for example—because their active forms may not reach bone tissue at adequate concentrations (63). Second, the non-linear, multi-target mode of action complicates the establishment of clear dose–effect relationships, making it difficult to define optimal therapeutic windows when moving from animal studies to human trials. Third, considerable inter-individual variability, especially in gut-microbiota composition and function, governs the metabolism and activation of many food bioactives and, ultimately, their biological effects (e.g., the conversion of polyphenols to active metabolites such as 4-HPA) (77, 78). Such variability presents a major barrier to achieving consistent clinical outcomes. Moreover, many current studies are confined to in vitro cellular experiments or animal models—such as ovariectomised rats and glucocorticoid-induced mice—and lack large-scale, multicentre, long-term follow-up clinical trials in humans. Certain clinical studies that do exist often involve small sample sizes and short follow-up periods, making it difficult to draw definitive conclusions regarding long-term effects on BMD and fracture risk. Thus, while multi-target activity is a strength, it simultaneously introduces complexity in standardization and in the reproducible assessment of efficacy.

Although pre-clinical studies have shown promise, the translation of plant-derived food bioactives into interventions for OP remains problematic. To realize their therapeutic potential, future work must move beyond descriptive validation and embrace mechanistically targeted investigation. Organoid and organ-on-a-chip technologies offer unprecedented investigative opportunities. By co-culturing intestinal organoids with marrow-derived osteoblasts or osteoclast precursors on microfluidic chips, a tractable “gut–bone axis” can be engineered (55). Such systems permit real-time examination, within a physiologically relevant microenvironment, of how specific bioactive metabolites—such as the polyphenol derivative 4-HPA (63)—or shifts in the microbial community directly modulate bone-cell behavior.

Future investigations should stratify participants on the basis of predictive biomarkers. These may comprise: (i) gut-microbiome profiles, such as the baseline abundance of polyphenol-metabolizing bacteria (78); (ii) metabolomic signatures, including levels of short-chain fatty acids or inflammatory metabolites (54); and (iii) genetic or epigenetic markers, for example polymorphisms in antioxidant-response or estrogen-signaling pathways. Interventions can then be tailored accordingly, and their efficacy evaluated against these biomarkers in conjunction with BMD.

Owing to the polygenic and multi-target nature of both OP pathogenesis and bioactive action, future work should systematically identify synergistic combinations. Examples already hint at benefit: resveratrol plus calcium/vitamin D mitigates spinal-cord-injury-induced bone loss (144), whereas lycopene combined with genistein is markedly protective in glucocorticoid-driven OP (100). Resveratrol-loaded hydrogels enhance osteogenic differentiation (177). Likewise, co-formulation of polyphenols with probiotics is being explored to enhance bioavailability and gut-mediated effects (80). Network-pharmacology and systems-biology frameworks should now be deployed to rationally optimize such combinations (122, 129).

Plant-derived food bioactives constitute a large and promising arsenal for the prevention and management of OP, characterized by multi-target activity and favorable safety profiles. The way forward is to adopt innovative models, design smarter clinical trials, apply cutting-edge technologies to dissect mechanisms, and develop engineered solutions to overcome bioavailability hurdles. By pursuing these targeted, interdisciplinary lines of research, we can accelerate the transition of these natural compounds from generic dietary constituents to validated, precise, and effective nutraceutical agents for bone health.

Author contributions

YiZ: Writing – original draft, Writing – review & editing. LX: Investigation, Writing – original draft. HX: Investigation, Project administration, Writing – review & editing. YirZ: Resources, Visualization, Writing – review & editing. LW: Investigation, Resources, Writing – review & editing. SJ: Investigation, Visualization, Writing – review & editing. YS: Writing – review & editing. YY: Writing – review & editing.

Conflict of interest

The author(s) declared that that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 1.

Suvarna

Sarkar

Chaubey

Khan

Sherje

Patel

. Bone health and natural products- an insight. Front Pharmacol. (2018) 9:981. doi: 10.3389/fphar.2018.00981

30283334

Xiao

Cui

Hsu

Peng

Jiang

. Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int. (2022) 33:2137–53. doi: 10.1007/s00198-022-06454-3

35687123

Lyu

Ramoo

Chui

Zhang

. Prevalence rate of primary osteoporosis in China: a meta-analysis. BMC Public Health. (2024) 24:1518. doi: 10.1186/s12889-024-18932-w

38844897

Chandran

. Brind'Amour K, Fujiwara S, Ha Y-C, Tang H, Hwang J-S, et al. Prevalence of osteoporosis and incidence of related fractures in developed economies in the Asia Pacific region: a systematic review. Osteoporos Int. (2023) 34:1037–53. doi: 10.1007/s00198-022-06657-8

Black

Rosen

. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. (2016) 374:254–62. doi: 10.1056/NEJMcp1513724

Qian

Xue

Tang

Wang

Song

Chyu

M-C

. Mitigation of oxidative damage by green tea polyphenols and Tai Chi exercise in postmenopausal women with osteopenia. PLoS ONE. (2012) 7:e48090. doi: 10.1371/journal.pone.0048090

23118932

Yang

Guo

Cai

. The association between total volume and intensity of moderate-to-vigorous physical activity and incidence of osteoporosis. Bone. (2025) 195:117461. doi: 10.1016/j.bone.2025.117461

40097034

Ensrud

Crandall

. Osteoporosis. Ann Intern Med. (2017) 167:ITC17–32. doi: 10.7326/AITC201708010

Diker-Cohen

Rosenberg

Avni

Shepshelovich

Tsvetov

Gafter-Gvili

. Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab. (2020) 105:dgz322. doi: 10.1210/clinem/dgz322

31899506

10.

Rossi

Serafini

Antonelli

Pierigé

Carnevali

Battistelli

. Macrophage depletion induced by clodronate-loaded erythrocytes. J Drug Target. (2005) 13:99–111. doi: 10.1080/10611860500064123

15823961

11.

Liu

Zhang

Shen

Zhang

Yin

. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: a network meta-analysis of randomized controlled trials. PLoS ONE. (2020) 15:e0243851. doi: 10.1371/journal.pone.0243851

33326444

12.

Sharma

Saini

Kumar

Goyal

. Pinus roxburghii alleviates bone porosity and loss in postmenopausal osteoporosis by regulating estrogen, calcium homeostasis and receptor activator of nuclear factor-κB, osteoprotegerin, cathepsin bone markers. J Pharm Pharmacol. (2021) 73:901–15. doi: 10.1093/jpp/rgaa014

33769535

13.

Karimi

Bayat

Rahimi

. Plant-derived natural medicines for the management of osteoporosis: a comprehensive review of clinical trials. J Tradit Complement Med. (2024) 14:1–18. doi: 10.1016/j.jtcme.2023.08.001

38223808

14.

Tabatabaei-Malazy

Larijani

Abdollahi

. Targeting metabolic disorders by natural products. J Diabetes Metab Disord. (2015) 14:57. doi: 10.1186/s40200-015-0184-8

26157708

15.

Perrone

De Rosa

D'Angelo

. Polyphenols and bone health: a comprehensive review of their role in osteoporosis prevention and treatment. Molecules. (2025) 30:4154. doi: 10.3390/molecules30214154

41226117

16.

Chen

Weng

Kalinowska

Xiong

Wang

Song

. Anti-osteoporosis effect of bioactives in edible medicinal plants: a comprehensive review. Crit Rev Food Sci Nutr. (2024) 65:4310–26. doi: 10.1080/10408398.2024.2386449

39093554

17.

Abdelnabi

Mohsin

. Phytochemicals in bone therapy: exploring natural alternatives for bone health. Int J Nanomedicine. (2025) 20:10831–55. doi: 10.2147/IJN.S524695

40918947

18.

Huang

W-Y

Cai

Y-Z

Zhang

. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer. (2010) 62:1–20. doi: 10.1080/01635580903191585

20043255

19.

Tetali

. Terpenes and isoprenoids: a wealth of compounds for global use. Planta. (2018) 249:1–8. doi: 10.1007/s00425-018-3056-x

30467631

20.

Sharma

Shah

Chigurupati

Ashokan

Meerasa

. Understanding the mechanistic potential of plant based phytochemicals in management of postmenopausal osteoporosis. Biomed Pharmacother. (2023) 163:114850. doi: 10.1016/j.biopha.2023.114850

37172332

21.

Pandey

Gupta

Karelia

Gilhooley

Shakibaei

Aggarwal

. Dietary nutraceuticals as backbone for bone health. Biotechnol Adv. (2018) 36:1633–48. doi: 10.1016/j.biotechadv.2018.03.014

29597029

22.

Yao

Liu

Fang

. Polyphenols as potential preventers of osteoporosis: a comprehensive review on antioxidant and anti-inflammatory effects, molecular mechanisms, and signal pathways in bone metabolism. J Nutr Biochem. (2023) 123:109488. doi: 10.1016/j.jnutbio.2023.109488

37865383

23.

Gao

Zhao

. The effects of β-carotene on osteoporosis: a systematic review and meta-analysis of observational studies. Osteoporos Int. (2023) 34:627–39. doi: 10.1007/s00198-022-06593-7

36380163

24.

Park

S-H

. Recent research on the role of phytochemicals from ginseng in management of osteosarcoma, osteoporosis, and osteoarthritis. Nutrients. (2025) 17:1910. doi: 10.3390/nu17111910

40507179

25.

Hadjidakis

Androulakis

. Bone remodeling. Ann N Y Acad Sci. (2006) 1092:385–96. doi: 10.1196/annals.1365.035

26.

Salhotra

Shah

Levi

Longaker

. Mechanisms of bone development and repair. Nat Rev Mol Cell Biol. (2020) 21:696–711. doi: 10.1038/s41580-020-00279-w

32901139

27.

Sanjaya

Park

Choi

Park

Sadanaga

Jung

M-J

. Polyphenol extract from Tagetes erecta L flowers stimulates osteogenesis via β-catenin activation. Phytomedicine. (2025) 136:156313. doi: 10.1016/j.phymed.2024.156313

28.

Vimalraj

. Alkaline phosphatase: structure, expression and its function in bone mineralization. Gene. (2020) 754:144855. doi: 10.1016/j.gene.2020.144855

32522695

29.

Datta

Walker

Tuck

Varanasi

. The cell biology of bone metabolism. J Clin Pathol. (2008) 61:577–87. doi: 10.1136/jcp.2007.048868

18441154

30.

Ponzetti

Rucci

. Osteoblast differentiation and signaling: established concepts and emerging topics. Int J Mol Sci. (2021) 22:6651. doi: 10.3390/ijms22136651

34206294

31.

Zhang

Oyajobi

Harris

Chen

Tsao

Deng

H-W

. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone. (2013) 52:145–56. doi: 10.1016/j.bone.2012.09.029

23032104

32.

Chen

Y-P

. TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. (2016) 4:16009. doi: 10.1038/boneres.2016.9

27563484

33.

Chen

Qian

Y-P

. Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease. Bone Res. (2024) 12:39. doi: 10.1038/s41413-024-00342-8

38987555

34.

Duan

Bonewald

. The role of the wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol. (2016) 77:23–9. doi: 10.1016/j.biocel.2016.05.015

27210503

35.

Sun

Luo

Guo

Yao

Jing

Guo

. The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthritis Cartilage. (2020) 28:400–9. doi: 10.1016/j.joca.2020.02.027

32081707

36.

Liu

Zhang

Luo

Peng

Wang

. Research on the role and mechanism of the PI3K/Akt/mTOR signalling pathway in osteoporosis. Front Endocrinol. (2025) 16:1541714. doi: 10.3389/fendo.2025.1541714

40421249

37.

Kim

J-M

Lin

Stavre

Greenblatt

Shim

J-H

. Osteoblast-osteoclast communication and bone homeostasis. Cells. (2020) 9:2073. doi: 10.3390/cells9092073

32927921

38.

Brage

Abrahamson

Lindström

Grubb

Lerner

. Different cysteine proteinases involved in bone resorption and osteoclast formation. Calcif Tissue Int. (2005) 76:439–47. doi: 10.1007/s00223-004-0043-y

15906014

39.

Piperigkou

Kyriakopoulou

Koutsakis

Mastronikolis

Karamanos

. Key matrix remodeling enzymes: functions and targeting in cancer. Cancers. (2021) 13:1441. doi: 10.3390/cancers13061441

33809973

40.

Udagawa

Koide

Nakamura

Nakamichi

Yamashita

Uehara

. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. (2021) 39:19–26. doi: 10.1007/s00774-020-01162-6

33079279

41.

Andersen

Sondergaard

Skorzynska

Dagnaes-Hansen

Plesner

Hauge

. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. (2009) 174:239–47. doi: 10.2353/ajpath.2009.080627

19095960

42.

De Leon-Oliva

Barrena-Blázquez

Jiménez-Álvarez

Fraile-Martinez

García-Montero

López-González

. The RANK-RANKL-OPG system: a multifaceted regulator of homeostasis, immunity, and cancer. Medicina. (2023) 59:1752. doi: 10.3390/medicina59101752

37893470

43.

Aeschlimann

Evans

BAJ

. The vital osteoclast: how is it regulated? Cell Death Differ. (2004) 11(Suppl 1):S5–7. doi: 10.1038/sj.cdd.4401470

15243577

44.

Kurotaki

Yoshida

Tamura

. Epigenetic and transcriptional regulation of osteoclast differentiation. Bone. (2020) 138:115471. doi: 10.1016/j.bone.2020.115471

32526404

45.

Welch

Hardcastle

. The effects of flavonoids on bone. Curr Osteoporos Rep. (2014) 12:205–10. doi: 10.1007/s11914-014-0212-5

24671371

46.

Yasuda

Shima

Nakagawa

Yamaguchi

Kinosaki

Mochizuki

. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. (1998) 95:3597–602. doi: 10.1073/pnas.95.7.3597

9520411

47.

Weitzmann

Ofotokun

. Physiological and pathophysiological bone turnover - role of the immune system. Nat Rev Endocrinol. (2016) 12:518–32. doi: 10.1038/nrendo.2016.91

27312863

48.

Giordani

Matacchione

Giuliani

Valli

Scarpa

Antonelli

. Pro-osteogenic and anti-inflammatory synergistic effect of orthosilicic acid, vitamin K2, curcumin, polydatin and quercetin combination in young and senescent bone marrow-derived mesenchymal stromal cells. Int J Mol Sci. (2023) 24:8820. doi: 10.3390/ijms24108820

37240169

49.

Wei

Chai

Yue

Zhang

Qin

. Resveratrol protects osteocytes against oxidative stress in ovariectomized rats through AMPK/JNK1-dependent pathway leading to promotion of autophagy and inhibition of apoptosis. Cell Death Discov. (2023) 9:16. doi: 10.1038/s41420-023-01331-2

36681672

50.

Kunnumakkara

Sailo

Banik

Harsha

Prasad

Gupta

. Chronic diseases, inflammation, and spices: how are they linked? J Transl Med. (2018) 16:14. doi: 10.1186/s12967-018-1381-2

29370858

51.

Livshits

Kalinkovich

. Targeting chronic inflammation as a potential adjuvant therapy for osteoporosis. Life Sci. (2022) 306:120847. doi: 10.1016/j.lfs.2022.120847

35908619

52.

Marahleh

Kitaura

Ohori

Kishikawa

Ogawa

Shen

W-R

. TNF-α directly enhances osteocyte RANKL expression and promotes osteoclast formation. Front Immunol. (2019) 10:2925. doi: 10.3389/fimmu.2019.02925

31921183

53.

Shakibaei

Buhrmann

Mobasheri

. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem. (2011) 286:11492–505. doi: 10.1074/jbc.M110.198713

21239502

54.

Zheng

X-Q

Wang

D-B

Jiang

Y-R

Song

C-L

. Gut microbiota and microbial metabolites for osteoporosis. Gut Microbes. (2025) 17:2437247. doi: 10.1080/19490976.2024.2437247

39690861

55.

Dong

Sun

Zhou

Gai

Cai

Han

. Modulation of the gut-bone axis: Lacticaseibacillus paracasei LC86 improves bone health via anti-inflammatory metabolic pathways in zebrafish models of osteoporosis and cartilage damage. Front Immunol. (2025) 16:1493560. doi: 10.3389/fimmu.2025.1493560

40308595

56.

Chen

Xie

. Progress of research on the gut microbiome and its metabolite short-chain fatty acids in postmenopausal osteoporosis: a literature review. Front Med. (2025) 19:474–92. doi: 10.1007/s11684-025-1129-3

40347368

57.

Scarpa

E-S

Antonelli

Balercia

Sabatelli

Maggi

Caprioli

. Antioxidant, anti-inflammatory, anti-diabetic, and pro-osteogenic activities of polyphenols for the treatment of two different chronic diseases: type 2 diabetes mellitus and osteoporosis. Biomolecules. (2024) 14:836. doi: 10.3390/biom14070836

39062550

58.

Wattel

Kamel

Prouillet

Petit

J-P

Lorget

Offord

. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J Cell Biochem. (2004) 92:285–95. doi: 10.1002/jcb.20071

15108355

59.

Andersson

Lindgren

. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 2647 cells through inhibition of ROS production. Biochem Biophys Res Commun. (2010) 401:356–62. doi: 10.1016/j.bbrc.2010.09.053

20851107

60.

Chang

J-K

Hsu

Y-L

Teng

Kuo

P-L

. Piceatannol stimulates osteoblast differentiation that may be mediated by increased bone morphogenetic protein-2 production. Eur J Pharmacol. (2006) 551:1–9. doi: 10.1016/j.ejphar.2006.08.073

17026990

61.

Choi

E-M

Hwang

J-K

. Effects of (+)-catechin on the function of osteoblastic cells. Biol Pharm Bull. (2003) 26:523–6. doi: 10.1248/bpb.26.523

62.

Cao

Hou

Xie

. Polyphenols and functionalized hydrogels for osteoporotic bone regeneration. Macromol Rapid Commun. (2025) 46:e2400653. doi: 10.1002/marc.202400653

39588839

63.

Zhang

Liu

Wang

Zheng

Wang

. 4-hydroxyphenylacetic acid, a microbial-derived metabolite of Polyphenols, inhibits osteoclastogenesis by inhibiting ROS production. Int Immunopharmacol. (2024) 143:113571. doi: 10.1016/j.intimp.2024.113571

39520963

64.

Bonkowski

Sinclair

. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. (2016) 17:679–90. doi: 10.1038/nrm.2016.93

27552971

65.

Baur

Sinclair

. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. (2006) 5:493–506. doi: 10.1038/nrd2060

16732220

66.

Zhao

Zhu

Hao

Zhang

. Anti-osteoporosis and bone protective effects of resveratrol in rats with chronic kidney disease-induced osteoporosis. Mol Nutr Food Res. (2025) 69:e70017. doi: 10.1002/mnfr.70017

40045654

67.

Shuid

Abdul Nasir

Ab Azis

Shuid

Razali

Ahmad Hairi

. A systematic review on the molecular mechanisms of resveratrol in protecting against osteoporosis. Int J Mol Sci. (2025) 26:2893. doi: 10.3390/ijms26072893

40243497

68.

Meyer

Brockmueller

Buhrmann

Shakibaei

. Prevention and co-management of breast cancer-related osteoporosis using resveratrol. Nutrients. (2024) 16:708. doi: 10.3390/nu16050708

38474838

69.

Yan

Wang

Liu

. Resveratrol ameliorates high altitude hypoxia-induced osteoporosis by suppressing the ROS/HIF signaling pathway. Molecules. (2022) 27:5538. doi: 10.3390/molecules27175538

36080305

70.

Sakr

Ammar

AlKharusi

Al-Lawati

AlKhateeb

Elesawy

. Resveratrol modulates bone mineral density and bone mineral content in a rat model of male hypogonadism. Chin J Integr Med. (2023) 29:146–54. doi: 10.1007/s11655-022-2895-2

35799086

71.

Zeng

Yang

Jiang

. Resveratrol reversed rosiglitazone administration induced bone loss in rats with type 2 diabetes mellitus. Biomed Pharmacother. (2024) 178:117208. doi: 10.1016/j.biopha.2024.117208

39088966

72.

Corbi

Nobile

Conti

Cannavo

Sorrenti

Medoro

. Equol and resveratrol improve bone turnover biomarkers in postmenopausal women: a clinical trial. Int J Mol Sci. (2023) 24:12063. doi: 10.3390/ijms241512063

37569440

73.

Xin

Cai

. The role of resveratrol in bone marrow-derived mesenchymal stem cells from patients with osteoporosis. J Cell Biochem. (2019) 120:16634–42. doi: 10.1002/jcb.28922

31106448

74.

Inchingolo

Malcangi

Avantario

Azzollini

Buongiorno

. Effects of resveratrol, curcumin and quercetin supplementation on bone metabolism-a systematic review. Nutrients. (2022) 14:3519. doi: 10.3390/nu14173519

36079777

75.

Zhao

Wang

Zhang

Yin

. Effects of dietary resveratrol on excess-iron-induced bone loss via antioxidative character. J Nutr Biochem. (2015) 26:1174–82. doi: 10.1016/j.jnutbio.2015.05.009

26239832

76.

Zamai

Corrêa

Ribeiro

Cirano

Casati

Messora

. Does resveratrol favor peri-implant bone repair in rats with ovariectomy-induced osteoporosis? Gene expression, counter-torque and micro-CT analysis. Braz Oral Res. (2023) 37:e003. doi: 10.1590/1807-3107bor-2023.vol37.0003

36700588

77.

Cardona

Andrés-Lacueva

Tulipani

Tinahones

Queipo-Ortuño

. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. (2013) 24:1415–22. doi: 10.1016/j.jnutbio.2013.05.001

23849454

78.

Meyer

Brockmueller

Ruiz de Porras

Shakibaei

. Microbiota and resveratrol: how are they linked to osteoporosis? Cells. (2024) 13:1145. doi: 10.3390/cells13131145

38994996

79.

Wen

. Study on the relationship between tea polyphenols alleviating osteoporosis and the changes of microorganism-metabolite-intestinal barrier. Microb Pathog. (2024) 188:106564. doi: 10.1016/j.micpath.2024.106564

38307369

80.

Huidrom

Beg

Masood

. Post-menopausal osteoporosis and probiotics. Curr Drug Targets. (2021) 22:816–22. doi: 10.2174/1389450121666201027124947

33109043

81.

Zheng

Wang

. Chen X. Intake of dietary flavonoids in relation to bone loss among US adults: a promising strategy for improving bone health. Food Funct. (2024) 15:766–78. doi: 10.1039/D3FO02065G

82.

Chen

. The potential mechanism of the microbiota-gut-bone axis in osteoporosis: a review. Osteoporos Int. (2022) 33:2495–506. doi: 10.1007/s00198-022-06557-x

36169678

83.

Lin

Chen

Lin

Dong

. Protective effect and possible mechanisms of resveratrol in animal models of osteoporosis: a preclinical systematic review and meta-analysis. Phytother Res. (2023) 37:5223–42. doi: 10.1002/ptr.7954

37482965

84.

Wong

Thaung Zaw

Xian

Howe

. Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res. (2020) 35:2121–31. doi: 10.1002/jbmr.4115

32564438

85.

Panahande

Maghbooli

Hossein-Nezhad

Qorbani

Moeini-Nodeh

Haghi-Aminjan

. Effects of French maritime pine bark extract (Oligopin^®) supplementation on bone remodeling markers in postmenopausal osteopenic women: a randomized clinical trial. Phytother Res. (2019) 33:1233–40. doi: 10.1002/ptr.6320

30907034

86.

Filip

Possemiers

Heyerick

Pinheiro

Raszewski

Davicco

. Twelve-month consumption of a polyphenol extract from olive (Olea europaea) in a double blind, randomized trial increases serum total osteocalcin levels and improves serum lipid profiles in postmenopausal women with osteopenia. J Nutr Health Aging. (2015) 19:77–86. doi: 10.1007/s12603-014-0480-x

25560820

87.

Shen

Chyu

Yeh

Zhang

Pence

Felton

. Effect of green tea and Tai Chi on bone health in postmenopausal osteopenic women: a 6-month randomized placebo-controlled trial. Osteoporos Int. (2011) 23:1541–52. doi: 10.1007/s00198-011-1731-x

21766228

88.

Asfha

Mishra

Vuppu

. Teff grain-based functional food for prevention of osteoporosis: sensory evaluation and molecular docking approach. Plant Foods Hum Nutr. (2022) 77:568–76. doi: 10.1007/s11130-022-01012-y

36094586

89.

Feresin

Johnson

Elam

Pourafshar

Navaei

Akhavan

. Effects of strawberries on bone biomarkers in pre- and stage 1-hypertensive postmenopausal women: a secondary analysis. Food Funct. (2021) 12:12526–34. doi: 10.1039/D1FO01555A

34812466

90.

Kim

Park

Pandey

Lee

Sohng

. Trilobatin ameliorates bone loss via suppression of osteoclast cell differentiation and bone resorptive function in vitro and in vivo. Life Sci. (2021) 270:119074. doi: 10.1016/j.lfs.2021.119074

33497739

91.

Rao

Mackinnon

Josse

Murray

Strauss

Rao

. Lycopene consumption decreases oxidative stress and bone resorption markers in postmenopausal women. Osteoporos Int. (2007) 18:109–15. doi: 10.1007/s00198-006-0205-z

16941193

92.

Maggio

Polidori

Barabani

Tufi

Ruggiero

Cecchetti

. Low levels of carotenoids and retinol in involutional osteoporosis. Bone. (2006) 38:244–8. doi: 10.1016/j.bone.2005.08.003

16188508

93.

Yang

Zhang

Penniston

Binkley

Tanumihardjo

. Serum carotenoid concentrations in postmenopausal women from the United States with and without osteoporosis. Int J Vitam Nutr Res. (2008) 78:105–11. doi: 10.1024/0300-9831.78.3.105

19003732

94.

Rao

. Carotenoids and human health. Pharmacol Res. (2007) 55:207–16. doi: 10.1016/j.phrs.2007.01.012

95.

Kim

Rao

. Lycopene II–effect on osteoblasts: the carotenoid lycopene stimulates cell proliferation and alkaline phosphatase activity of SaOS-2 cells. J Med Food. (2003) 6:79–86. doi: 10.1089/109662003322233468

12935317

96.

Oliveira

Vargas-Sanchez

Fernandes

Ricoldi

MST

Semeghini

Pitol

. Lycopene influences osteoblast functional activity and prevents femur bone loss in female rats submitted to an experimental model of osteoporosis. J Bone Miner Metab. (2019) 37:658–67. doi: 10.1007/s00774-018-0970-8

30357566

97.

Ardawi

M-SM

Badawoud

Hassan

Rouzi

Ardawi

JMS

AlNosani

. Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model. Bone. (2016) 83:127–40. doi: 10.1016/j.bone.2015.10.017

26549245

98.

Mackinnon

Rao

Josse

Rao

. Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in postmenopausal women. Osteoporos Int. (2011) 22:1091–101. doi: 10.1007/s00198-010-1308-0

20552330

99.

Semeghini

Scalize

Coelho

Fernandes

Pitol

Tavares

. Lycopene prevents bone loss in ovariectomized rats and increases the number of osteocytes and osteoblasts. J Anat. (2022) 241:729–40. doi: 10.1111/joa.13672

35445391

100.

Mannino

D'Angelo

Pallio

Ieni

Pirrotta

Giorgi

. The nutraceutical genistein-lycopene combination improves bone damage induced by glucocorticoids by stimulating the osteoblast formation process. Nutrients. (2022) 14:4296. doi: 10.3390/nu14204296

36296984

101.

Tao

Z-S

X-J

Yang

Shen

C-L

. Astaxanthin prevents bone loss in osteoporotic rats with palmitic acid through suppressing oxidative stress. Redox Rep. (2024) 29:2333096. doi: 10.1080/13510002.2024.2333096

38623993

102.

Algandaby

. Crocin attenuates metabolic syndrome-induced osteoporosis in rats. J Food Biochem. (2019) 43:e12895. doi: 10.1111/jfbc.12895

31353703

103.

Tanaka

Tominari

Takatoya

Arai

Sugasaki

Ichimaru

. Lutein maintains bone mass in vitro and in vivo against disuse-induced bone loss in hindlimb-unloaded mice. Nutrients. (2024) 16:4271. doi: 10.3390/nu16244271

39770893

104.

Sahni

Hannan

Blumberg

Cupples

Kiel

Tucker

. Inverse association of carotenoid intakes with 4-y change in bone mineral density in elderly men and women: the Framingham Osteoporosis Study. Am J Clin Nutr. (2009) 89:416–24. doi: 10.3945/ajcn.2008.26388

19056581

105.

Chen

Yuan

Yang

Zuo

. Diet-derived antioxidants and osteoporosis: A Mendelian randomization study. PLoS ONE. (2023) 18:e0293145. doi: 10.1371/journal.pone.0293145

38019728

106.

Dai

Wang

Ang

L-W

Low

Y-L

Yuan

J-M

Koh

W-P

. Protective effects of dietary carotenoids on risk of hip fracture in men: the Singapore Chinese Health Study. J Bone Miner Res. (2014) 29:408–17. doi: 10.1002/jbmr.2041

23857780

107.

Zhang

Wei

Cui

Zhou

. Composite dietary antioxidant intake and osteoporosis likelihood in premenopausal and postmenopausal women: a population-based study in the United States. Menopause. (2023) 30:529–38. doi: 10.1097/GME.0000000000002173

36944153

108.

Regu

Kim

Paek

Lee

Chang

. Association between dietary carotenoid intake and bone mineral density in korean adults aged 30-75 years using data from the Fourth and Fifth Korean National Health and Nutrition Examination Surveys (2008-2011). Nutrients. (2017) 9:1025. doi: 10.3390/nu9091025

28926945

109.

Kim

Cho

Park

Chang

. Relationship between bone mineral density and dietary intake of β-carotene, vitamin C, zinc and vegetables in postmenopausal Korean women: a cross-sectional study. J Int Med Res. (2016) 44:1103–14. doi: 10.1177/0300060516662402

27664069

110.

Sugiura

Nakamura

Ogawa

Ikoma

Yano

. High vitamin C intake with high serum β-cryptoxanthin associated with lower risk for osteoporosis in post-menopausal japanese female subjects: Mikkabi Cohort Study. J Nutr Sci Vitaminol. (2016) 62:185–91. doi: 10.3177/jnsv.62.185

27465725

111.

Sahni

Hannan

Blumberg

Cupples

Kiel

Tucker

. Protective effect of total carotenoid and lycopene intake on the risk of hip fracture: a 17-year follow-up from the Framingham Osteoporosis Study. J Bone Miner Res. (2009) 24:1086–94. doi: 10.1359/jbmr.090102

19138129

112.

Hayhoe

RPG

Lentjes

MAH

Mulligan

Luben

Khaw

K-T

Welch

. Carotenoid dietary intakes and plasma concentrations are associated with heel bone ultrasound attenuation and osteoporotic fracture risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. Br J Nutr. (2017) 117:1439–53. doi: 10.1017/S0007114517001180

113.

Sugiura

Nakamura

Ogawa

Ikoma

Yano

. High serum carotenoids associated with lower risk for bone loss and osteoporosis in post-menopausal Japanese female subjects: prospective cohort study. PLoS ONE. (2012) 7:e52643. doi: 10.1371/journal.pone.0052643

23285126

114.

Sun

L-l

B-l

Xie

H-l

Fan

W-z

B-h

. Associations between the dietary intake of antioxidant nutrients and the risk of hip fracture in elderly Chinese: a case-control study. Br J Nutr. (2014) 112:1706–14. doi: 10.1017/S0007114514002773

25287150

115.

Kan

Guo

Yuan

Vuong

Jiang

Zhang

. Dietary carotenoid intake and osteoporosis: the National Health and Nutrition Examination Survey, 2005-2018. Arch Osteoporos. (2021) 17:2. doi: 10.1007/s11657-021-01047-9

34878583

116.

Nian

Qin

L-P

Chen

W-S

Zhang

Q-Y

Zheng

H-C

Wang

. Protective effect of steroidal saponins from rhizome of Anemarrhena asphodeloides on ovariectomy-induced bone loss in rats. Acta Pharmacol Sin. (2006) 27:728–34. doi: 10.1111/j.1745-7254.2006.00328.x

16723092

117.

Zhang

Huang

Liu

Zhou

Yuan

Jiang

. Molecular mechanism of ginsenoside Rg3 alleviation in osteoporosis via modulation of KPNA2 and the NF-κB signalling pathway. Clin Exp Pharmacol Physiol. (2025) 52:e70019. doi: 10.1111/1440-1681.70019

39821958

118.

Mai

Guo

Ding

. Ginsenoside Rb2 exhibits therapeutic value for male osteoporosis in orchiectomy mice by suppressing osteoclastogenesis and modulating NF-κB/MAPK signaling pathways. Food Funct. (2024) 15:1583–97. doi: 10.1039/D3FO04334G

38240189

119.

Jiang

Deng

Alonge

Wang

. Ginsenoside Rg1 modulates PI3K/AKT pathway for enhanced osteogenesis via GPER. Phytomedicine. (2024) 124:155284. doi: 10.1016/j.phymed.2023.155284

38176267

120.

Zhang

Suo

. Ginsenoside Rb1 prevents osteoporosis via the AHR/PRELP/NF-κB signaling axis. Phytomedicine. (2022) 104:154205. doi: 10.1016/j.phymed.2022.154205

35716470

121.

Huang

Gao

Jie

Wei

B-Y

Fan

Zhang

H-Y

. Ginsenoside-Rb2 displays anti-osteoporosis effects through reducing oxidative damage and bone-resorbing cytokines during osteogenesis. Bone. (2014) 66:306–14. doi: 10.1016/j.bone.2014.06.010

24933344

122.

Guo

Zhen

Cui

Jiang

Zhang

. A network pharmacology approach to explore and validate the potential targets of ginsenoside on osteoporosis. Int J Immunopathol Pharmacol. (2022) 36:3946320221107239. doi: 10.1177/03946320221107239

35791093

123.

Song

Jia

Cao

Zhang

Liu

Gao

. Ginsenoside Rg3 attenuates aluminum-induced osteoporosis through regulation of oxidative stress and bone metabolism in rats. Biol Trace Elem Res. (2020) 198:557–66. doi: 10.1007/s12011-020-02089-9

32173789

124.

Zhu

Zheng

Miao

Yan

. Ginsenoside Rb1 alleviates aluminum chloride-induced rat osteoblasts dysfunction. Toxicology. (2016) 368–9; 183-8. doi: 10.1016/j.tox.2016.07.014

27470910

125.

Cao

Wang

. A novel triterpenoid saponin from Pimpinella candolleana alleviates postmenopausal osteoporosis via P38/JNK MAPK-mediated osteogenesis. Phytomedicine. (2025) 145:157004. doi: 10.1016/j.phymed.2025.157004

40609388

126.

Wenxi

Shufang

Xiaoling

Liming

. Panax notoginseng saponins suppress radiation-induced osteoporosis by regulating bone formation and resorption. Phytomedicine. (2015) 22:813–9. doi: 10.1016/j.phymed.2015.05.056

26220628

127.

S-Y

. Therapeutic potential of ginsenosides on bone metabolism: a review of osteoporosis, periodontal disease and osteoarthritis. Int J Mol Sci. (2024) 25:5828. doi: 10.3390/ijms25115828

38892015

128.

Yang

Zhang

Zhao

. Ginsenoside Rc promotes bone formation in ovariectomy-induced osteoporosis in vivo and osteogenic differentiation in vitro. Int J Mol Sci. (2022) 23:6187. doi: 10.3390/ijms23116187

35682866

129.

Zhang

Shen

Fan

. Biochemical targets and molecular mechanism of ginsenoside compound K in treating osteoporosis based on network pharmacology. Int J Mol Sci. (2022) 23:3921. doi: 10.3390/ijms232213921

36430397

130.

Bei

Zhang

Lin

. Ginsenoside Rb1 does not halt osteoporotic bone loss in ovariectomized rats. PLoS ONE. (2018) 13:e0202885. doi: 10.1371/journal.pone.0202885

30212470

131.

Liu

L-X

Tong

L-J

H-Y

Guo

Sun

Z-M

. Therapeutic effects of ginsenosides on osteoporosis for novel drug applications. Eur J Pharmacol. (2024) 974:176604. doi: 10.1016/j.ejphar.2024.176604

38649090

132.

Yuan

Wang

Guo

. Aflatoxin B1 contamination reduces the saponins content and anti-osteoporosis efficacy of the traditional medicine Radix Dipsaci. J Ethnopharmacol. (2025) 337:118857. doi: 10.1016/j.jep.2024.118857

39362329

133.

Guan

Yang

Zeng

Yang

. A novel strategy for the multi-components division and discovering pharmacodynamic material basis of Chinese herbal compounds: a case study of Xian-Ling-Gu-Bao capsule. J Pharm Biomed Anal. (2024) 243:116112. doi: 10.1016/j.jpba.2024.116112

38513502

134.

Yue

Tian

Bai

Wang

. Comparative study of holothurin A and echinoside A on inhibiting the high bone turnover via downregulating PI3K/AKT/β-catenin and OPG/RANKL/NF-κB signaling in ovariectomized mice. Food Funct. (2022) 13:4748–56. doi: 10.1039/D1FO04357A

35389397

135.

Zhou

Zhang

Qian

Tang

Zhou

Xie

. Ziyuglycoside II attenuated OVX mice bone loss via inflammatory responses and regulation of gut microbiota and SCFAs. Int Immunopharmacol. (2024) 132:112027. doi: 10.1016/j.intimp.2024.112027

38603860

136.

Chen

Zou

Wei

Liu

. Panax notoginseng saponins prevent bone loss by promoting angiogenesis in an osteoporotic mouse model. Biomed Res Int. (2020) 2020:8412468. doi: 10.1155/2020/8412468

33415157

137.

Choi

C-W

Choi

S-W

Kim

H-J

Lee

K-S

Kim

S-H

Kim

S-L

. Germinated soy germ with increased soyasaponin Ab improves BMP-2-induced bone formation and protects against in vivo bone loss in osteoporosis. Sci Rep. (2018) 8:12970. doi: 10.1038/s41598-018-31118-w

30154422

138.

Jin

Ren

Yang

Wang

. Astragaloside IV protects against iron loading-induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs). FEBS Open Bio. (2021) 11:1223–36. doi: 10.1002/2211-5463.13082

33445204

139.

Yang

Xie

Lei

Song

Gong

Liu

. Tubeimoside I suppresses diabetes-induced bone loss in rats, osteoclast formation, and RANKL-induced nuclear factor-κB pathway. Int Immunopharmacol. (2020) 80:106202. doi: 10.1016/j.intimp.2020.106202

32004923

140.

Wang

Shou

. Timosaponin BII improved osteoporosis caused by hyperglycemia through promoting autophagy of osteoblasts via suppressing the mTOR/NFκB signaling pathway. Free Radic Biol Med. (2021) 171:112–23. doi: 10.1016/j.freeradbiomed.2021.05.014

33992678

141.

Dai

Quarles

Song

Pan

Zhou

. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine. (2007) 14:806–14. doi: 10.1016/j.phymed.2007.04.003

17689939

142.

Hsu

Y-L

Chang

J-K

Tsai

C-H

Chien

T-TC

Kuo

P-L

. Myricetin induces human osteoblast differentiation through bone morphogenetic protein-2/p38 mitogen-activated protein kinase pathway. Biochem Pharmacol. (2007) 73:504–14. doi: 10.1016/j.bcp.2006.10.020

17113042

143.

Zhou

Shang

Zhang

Gao

Guo

. RETRACTED: resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Exp Cell Res. (2009) 315:2953–62. doi: 10.1016/j.yexcr.2009.07.030

19665018

144.

Zhong

. Resveratrol enhances the protective effects of calcium supplements on spinal cord injury-induced osteoporosis by targeting the SIRT1/FOXO3a pathway. Naunyn Schmiedebergs Arch Pharmacol. (2025) 398:2823–32. doi: 10.1007/s00210-024-03412-0

39287671

145.

Liu

Long

Chen

. Molecular mechanism of resveratrol promoting differentiation of preosteoblastic MC3T3-E1 cells based on network pharmacology and experimental validation. BMC Complement Med Ther. (2024) 24:108. doi: 10.1186/s12906-024-04396-3

38424533

146.

Y-J

Yang

Sui

B-D

C-H

Zhao

Liao

. Resveratrol counteracts bone loss via mitofilin-mediated osteogenic improvement of mesenchymal stem cells in senescence-accelerated mice. Theranostics. (2018) 8:2387–406. doi: 10.7150/thno.23620

29721087

147.

Luo

Cui

Jin

. The effects of resveratrol in animal models of primary osteoporosis: a systematic review and meta-analysis. J Orthop Surg Res. (2024) 19:137. doi: 10.1186/s13018-024-04595-1

38350991

148.

Feng

Y-L

Jiang

X-T

F-F

Han

Tang

X-L

. Resveratrol prevents osteoporosis by upregulating FoxO1 transcriptional activity. Int J Mol Med. (2018) 41:202–12. doi: 10.3892/ijmm.2017.3208

29115382

149.

Zhang

Liu

M-W

Deng

Chen

Huang

. Protective effect of resveratrol on estrogen deficiency-induced osteoporosis though attenuating NADPH oxidase 4/nuclear factor kappa B pathway by increasing miR-92b-3p expression. Int J Immunopathol Pharmacol. (2020) 34:2058738420941762. doi: 10.1177/2058738420941762

32674689

150.

Guo

D-W

Han

Y-X

Cong

Liang

G-J

. Resveratrol prevents osteoporosis in ovariectomized rats by regulating microRNA-338-3p. Mol Med Rep. (2015) 12:2098–106. doi: 10.3892/mmr.2015.3581

25845653

151.

Feng

Liu

Zhao

Zhang

. Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-κB signaling pathway. Acta Biochim Biophys Sin. (2014) 46:1024–33. doi: 10.1093/abbs/gmu103

25377437

152.

Karunarathne

WAHM

Molagoda

IMN

Lee

Choi

Jin

C-Y

Kim

G-Y

. Anthocyanin-enriched polyphenols from Hibiscus syriacus L. (Malvaceae) exert anti-osteoporosis effects by inhibiting GSK-3β and subsequently activating β-catenin. Phytomedicine. (2021) 91:153721. doi: 10.1016/j.phymed.2021.153721

153.

Perna

Ruina

Acharya

Mazzola

Rondanelli

Riso

. Berries derived polyphenols and bone health: a systematic review. Nutrients. (2025) 17:3440. doi: 10.3390/nu17213440

41228518

154.

Yang

Y-J

Zhu

Wang

D-T

. Zhang X-l, Liu Y-Y, Lai W-X, et al. Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPARγ2 signaling in GIO rats. Acta Pharmacol Sin. (2018) 39:633–41. doi: 10.1038/aps.2017.134

155.

Mei

Meng

Yun

Zhang

. Arecanut (Areca catechu L) seed polyphenol-ameliorated osteoporosis by altering gut microbiome via LYZ and the immune system in estrogen-deficient rats. J Agric Food Chem. (2021) 69:246–58. doi: 10.1021/acs.jafc.0c06671

33382620

156.

Zhao

Chen

Wang

. Anti-osteoporosis activity of lycopene through ESR1: network pharmacology, molecular docking, imaging technology, and experimental validation. Chem Biol Drug Des. (2025) 105:e70135. doi: 10.1111/cbdd.70135

40504801

157.

Xia

Dai

Shi

Yin

Liu

. Lycopene promotes osteogenesis and reduces adipogenesis through regulating FoxO1/PPARγ signaling in ovariectomized rats and bone marrow mesenchymal stem cells. Nutrients. (2024) 16:1443. doi: 10.20944/preprints202404.0288.v1

38794681

158.

Wang

Heng

Song

Zhai

Zhang

Geng

. Lycopene improves bone quality in samp6 mice by inhibiting oxidative stress, cellular senescence, and the SASP. Mol Nutr Food Res. (2023) 67:e2300330. doi: 10.1002/mnfr.202300330

37880898

159.

Hwang

Y-H

Kim

K-J

Kim

S-J

Mun

S-K

Hong

S-G

Son

Y-J

. Suppression effect of astaxanthin on osteoclast formation in vitro and bone loss in vivo. Int J Mol Sci. (2018) 19:912. doi: 10.3390/ijms19030912

29562730

160.

Huang

Zhu

Gao

Fang

. Lutein suppresses oxidative stress and inflammation by Nrf2 activation in an osteoporosis rat model. Med Sci Monit. (2018) 24:5071–5. doi: 10.12659/MSM.908699

30030965

161.

Zhang

Huang

Chen

Zhu

. Ginsenoside Rg3 attenuates ovariectomy-induced osteoporosis via AMPK/mTOR signaling pathway. Drug Dev Res. (2020) 81:875–84. doi: 10.1002/ddr.21705

32898934

162.

Yang

Xie

Wang

Shi

. Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model. Sci Rep. (2016) 6:35233. doi: 10.1038/srep35233

27756897

163.

Jiang

Yang

Guan

. Panax notoginseng saponins regulate angiogenic cytokines through the PI3K/AKT/mTOR signaling pathway to promote fracture healing in ovariectomized rats. J Med Food. (2024) 27:824–33. doi: 10.1089/jmf.2024.k.0014

38868856

164.

Zhang

Chen

Wei

Liu

Lei

Bai

. Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway. Chem Biol Interact. (2016) 256:188–97. doi: 10.1016/j.cbi.2016.07.003

27387537

165.

X-H

Dou

Sun

N-Y

Gao

Liu

X-L

. Astragalus saponin IV promotes osteogenic differentiation of bone marrow mesenchymal stem cells via miR-21/NGF/BMP2/Runx2 pathway. Acta Histochem. (2020) 122:151549. doi: 10.1016/j.acthis.2020.151549

32381364

166.

Kim

S-H

Yuk HJ Ryu

S-R

Song

Lee

K-S

. Biofunctional soyasaponin Bb in peanut (Arachis hypogaea L) sprouts enhances bone morphogenetic protein-2-dependent osteogenic differentiation via activation of runt-related transcription factor 2 in C2C12 cells. Phytother Res. (2019) 33:1490–500. doi: 10.1002/ptr.6341

30883927

167.

Zinnia

Khademul Islam

ABMM

. Fenugreek steroidal saponins hinder osteoclastogenic bone resorption by targeting CSF-1R which diminishes the RANKL/OPG ratio. Int J Biol Macromol. (2021) 186:351–64. doi: 10.1016/j.ijbiomac.2021.06.197

34217743

168.

Choi

Han

Kim

Jin

Lee

Jeong

. Platycodin D inhibits osteoclastogenesis by repressing the NFATc1 and MAPK signaling pathway. J Cell Biochem. (2017) 118:860–8. doi: 10.1002/jcb.25763

27739107

169.

Zhou

Liu

Wang

Chen

Song

. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways. Int Immunopharmacol. (2015) 25:49–54. doi: 10.1016/j.intimp.2015.01.010

25617149

170.

Lee

Jang

Lee

S-H

Nan

B-C

. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos. Bone. (2012) 50:1207–13. doi: 10.1016/j.bone.2012.03.022

22484180

171.

Niu

Tian

Zhang

Zhou

Wang

. Astragaloside IV alleviates macrophage senescence and d-galactose-induced bone loss in mice through STING/NF-κB pathway. Int Immunopharmacol. (2024) 129:111588. doi: 10.1016/j.intimp.2024.111588

38290207

172.

Fan

Zhang

Ding

Huang

Lian

. Unraveling Ginsenoside R1′s osteoprotective pathways in zebrafish models of glucocorticoid induced osteoporosis via transcriptomics. Sci Rep. (2025) 15:30519. doi: 10.1038/s41598-025-15284-2

173.

Sun

N-Y

Liu

X-L

Gao

X-H

Dou

. Astragaloside-IV modulates NGF-induced osteoblast differentiation via the GSK3β/β-catenin signalling pathway. Mol Med Rep. (2021) 23:19. doi: 10.3892/mmr.2020.11657

174.

Wei

Ruan

Dong

Yang

Zhang

Kelvin Yeung

. Asperosaponin VI inhibition of DNMT alleviates GPX4 suppression-mediated osteoblast ferroptosis and diabetic osteoporosis. J Adv Res. (2024) 75:331–44. doi: 10.1016/j.jare.2024.11.036

39647633

175.

Yousefzadeh

Kashfi

Jeddi

Ghasemi

. Ovariectomized rat model of osteoporosis: a practical guide. EXCLI J. (2020) 19:89–107. doi: 10.17179/excli2019-1990

32038119

176.

Compston

. Glucocorticoid-induced osteoporosis: an update. Endocrine. (2018) 61:7–16. doi: 10.1007/s12020-018-1588-2

29691807

177.

Shi

Bei

Wang

. An injectable thermosensitive hydrogel containing resveratrol and dexamethasone-loaded carbonated hydroxyapatite microspheres for the regeneration of osteoporotic bone defects small. Methods. (2023) 8:e2300843. doi: 10.1002/smtd.202300843

Edited by: Zhao-Jun Wei, North Minzu University, China

Reviewed by: Jun Wang, Hefei University, China

Fan Zhang, Anhui Normal University, China